

Summarized Curriculum Vitae

María J. Vicent, PhD

30th Dec 2025

ORCID number: 0000-0001-7771-3373

ResearcherID: A-9690-2014

Scopus Author ID: 6701442649



DOB: 24th December 1973 - <http://www.VicentResearchLab.com>

Indicators of Scientific Production

H Index: 55. Citations: 10267/i10: 130 (Google Scholar)

Publications: 163 (In last 5 years: 57, from those: 57 in Q1 and as corresponding author 39)

Patents: 15 (8 licensed, or in exploitation 1 as foundation of spin off company PTS SL in 2012, now a CDMO named Curapath after acquisition by Arcline Equity with 100 employees)

Projects as PI or Coordinator: 53, **Funding raised:** >22M€

PhD Thesis: 22 supervised (4 with Extraordinary Prizes) and 15 ongoing, with 5 industrial PhDs

Current Position(s)

2006-now Principal Investigator. Head of Polymer Therapeutics Lab. CIPF, Valencia, Spain.

2009-now Scientific responsible of CIPF Screening Platform an Accredited Site Specialist Site within the European Infrastructure (ERIC) EU-OpenScreen.

2019-now Vice-president Specialized Chemical Biology Section of the Spanish Royal Society of Chemistry (GQB-RSEQ)

2020-now Member of the Internal Advisory Board of the Scientific Foundation of the 'Consorcio Hospitalario Provincial de Castellón' (CHPC), Spain

2021-now Member of the International Advisory Board at Regional Institute of Oncology and TRANSCEND Research Center in Iasi, Romania

2021-now Manager at the 'Agencia Estatal de Investigación' (AEI) in the Science and Technology of Materials Area- Materials for Biomedicine Subarea, Spain

2021-now Chair of the Scientific Advisory Board at Polypeptide Therapeutic Solutions SL now known as Curapath (www.curapath.com)

2021-now Co-Founder and member of the board of directors of the Spanish Drug Discovery and Development Network (SDDN)

2022-now Member of the International Advisory Board of FoRmulaEx consortium, Sweden

2022-now Member of the "Centro de Investigación Biomédica en Red de Cáncer" (CIBERONC), Spain

2023-now Member of the International Advisory Board of CURAM. SFI Research Center for Medical Devices (Galway Univ, Ireland)

2023-now Editor In Chief Advanced Drug Delivery Reviews. Elsevier.

(<https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/about/editorial-board>)

2024-now Cancer Program Coordinator at CIPF, Valencia, Spain.

2024-now member of the International Advisory Board (IAB) of the Institute of Macromolecular Chemistry. Prague, Czech Republic

2024-now. Member of the International Advisory Board of NanoGrow.

2024- now Fellow of the National Academy of Inventors (FNAI), USA.

2024-now Executive Board of Directors Controlled Release Society (CRS). President Elect. USA

2024-now Board of Directors, International Committee Co-Chair, American Institute for Medical and Biological Engineering (AIMBE), USA.

2025-now Distinguished Researcher at the Medicine Department of Jaume I University, Spain

Previous Positions

2023-2024 Executive Board of Directors Controlled Release Society (CRS). Secretary. USA

2021-2023 Director at Large Controlled Release Society (CRS). Focus Groups Liaison, USA

2019-2021 Member of the International Advisory Board of Institute of Nanoscience and Nanotechnology University Barcelona (IN2UB)

2019-2023 Associate European Editor of Drug Delivery and Translation Research (DDTR, Springer)

2018-2023 Coordinator health Area Strategic committee of the Innovation Agency of the Valencian Community (AVI)

2016-2023 Executive Editor of Advanced Drug Delivery Reviews (ADDR, Elsevier).

2015-2023 Coordinator of the Advanced Therapies Area at CIPF, Valencia, Spain
2015-2019 Coordinator of Valencian Community Drug Discovery/Innovative Medicine Strategy.
2012-2021 Co-founder and CSO of Polypeptide Therapeutic Solutions SL (now Curapath)
2012-2015 Associate Professor. Organic Chemistry Department. University of Valencia, Spain
2004-2006 Associate Researcher (Marie Curie Reintegration Contract). CIPF, Valencia, Spain.
2002-2004 Postdoctoral Researcher (Marie Curie Individual fellowship) Prof. R. Duncan. Center for Polymer Therapeutics. Welsh School of Pharmacy. Cardiff University. Cardiff, UK
2001-2002 Visiting Postdoctoral Scientist, Instituto Biomar S.A. Madrid, Spain
2001-2002 UJI Postdoctoral Fellow from Univ. Jaume I. Organic Chemistry Dept. Univ. Jaume I, Spain.
1997-2000 Visiting Scientist (total of 18 moths) Prof. J.M.J. Fréchet. Dept. Chemistry Univ. California at Berkeley, Berkeley, CA (USA)
1997-2000 FPU PhD Fellow from Spanish Ministry. Organic Chemistry Dpt. Univ. Jaume I, Spain.

Awards and Recognitions

2025 Extraordinary distinction for Scientific merits by University Jaume I Castellón, Spain.
2025 Rei Jaume I Award on New Technologies. Foundation Rei Jaume I. Spain
2025 La Noticia del Año. Diario Digital. Castellón, Spain
2024 Samyang Award in Honor of Sung Wan Kim. Controlled Release Society (CRS), USA.
2024 Fellow of the National Academy of Inventors (FNAI), USA.
2023 Innovation Award. Diputació Castelló. Spain
2023 Women in Science (WIS) Award Controlled Release Society (CRS), USA
2022 Castellón Radio-Cadena Ser Science Award 2022, Spain
2022 European Research Council (ERC)-Proof of Concept Grant. POLYBRAINT
2021 Fellow of the Controlled Release Society (CRS) College of Fellows, USA
2021 "CONCEPCIÓN ALEIXANDRE" Women in Science Award, Category Valencian Community. Ajuntament Picanya.
2021 Accreditation as Professor by ANECA, Spain
2019 Fellow of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows, USA.
2018 ERC-Proof of Concept Grant. POLYIMMUNE
2015 ERC-Consolidator Grant. ERC-2014-CoG - 648831_MyNano.
2015 IX Certamen Valencia Idea. Award on "Biotechnology and Biomedicine Category", Spain.
2015 Excellence on Research Acknowledge by Conselleria Sanitat, Generalitat Valenciana, Spain.
2015-2019 Board member of the Specialized Chemical Biology Section of the Spanish Royal Society of Chemistry (GQB-RSEQ)
2011-2013 President of the Spanish-Portuguese Local Chapter of the Controlled Release Society (SPLC-CRS)
2012 'Poble Award' on international recognition from Revista Poble, Vila-real, Spain
2011 I3 Excellence Grant Award. MINECO Spanish Ministry.
2006-2011 Spanish Vice-president of the Spanish-Portuguese Local Chapter of the Controlled Release Society (SPLC-CRS)
2008 Award on Basic Sciences, IV Edition Idea Awards. Fundación Artes y Ciencias, Valencia, Spain.
2007 Ramon y Cajal Grant award. Spanish Ministry. MICINN.
2004 Marie Curie Reintegration Grant, European Commission
2002 Marie Curie Postdoctoral Research fellowship
2002 MICINN. Fulbright Scheme Postdoctoral research fellowship (decline in favor of Marie Curie grant)
1997-2000 MICINN Short Research Stays Grants (4x). Visiting scientist as UC Berkeley. Spanish Ministry.
1997 FPU MICINN predoctoral grant, Spanish Ministry

Funding ID. Research Grants.

Since 2006 Dr Vicent is Principal Investigator of research grants founded by National Agencies (Public and Private including Fund Health La Caixa-NanoPanTher or PINT as coordinator), European Funding Agencies (3 ERANet proposals an ERC Consolidator Grant-MyNano in 2015 and ERC-Proof of Concept 2018, 2021 as *coordinator*) and Industry. This has allowed her to directly contribute to a research income of >20 M€

Selected Main Competitive Grants

- 1. MITONano:** Grants from the Scientific Foundation of the Spanish Association Against Cancer (**AECC General Projects**; Ref: PRYGN259257VICE). Title: Targeting Mitochondrial Vulnerabilities with Nanomedicines for the Treatment of Peritoneal Carcinomatosis. LENGTH: 1/11/2025-30/10/2029 PI: María J. Vicent

2. **NanoERT**: nano-delivery platform for Enzyme Replacement Therapy in Parkinson's and Gaucher's disease. Funding agency: "la Caixa" Banking Foundation **Caixa Impulse Innovation 2024** Call. LENGTH: 1/11/2024-30/04/2026. Coordinator: Julia Lorenzo (UAB). Co-PIs: Marta Martínez and María J Vicent.
3. **PINT**: Precision ImmuneNanoTherapy targeting tumor-immune-stroma interactions against pancreatic cancer (HR24-00968) Funding agency: **Health Foundation La Caixa**. LENGTH: 1/11/2024-30/10/2027. Coordinator: MJ Vicent, PI: H Florindo, R. Satchi-Fainaro
4. **Point2Mets**: A Multimodal Precision Polypeptide-based Nanoplatfom to Treat and Monitor Metastatic Castration Resistance PCa. **AEI Plan Nacional I+D 2023**. Ref. **PID2023-152459OB-I00**. LENGTH: 1/09/2024-31/08/2027. PI: María J. Vicent co-PI: A. Armíñán.
5. **ASPIRE**: Grants from the Scientific Foundation of the Spanish Association Against Cancer **AECC 70% Survivorship Challenge -Call 2024**. Title: Neoadjuvant-adjuvant immunotherapy to improve survival in hepatocellular carcinoma. Team Coordinators: Josep M Llovet (Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS) Hospital Clínic Barcelona (HCB) Barcelona and Xosé R. Bustelo (Centro de Investigación del Cáncer (CIC), Salamanca). MJVicent WPLleader and member of Steering Committee.
6. **NATPRIME**: Effective Delivery of Nucleic Acid Therapeutics via Designed Nanocarriers (HORIZON-MSCA-2023-DN01. Proposal n.101168881) Funding Agency: **Horizon Europe MSCA**. LENGTH: 2024-2027. PIs: Coordinator: R. Bezer (Univ Warwick, UK) MJVicent PI Partner at CIPF.
7. **UNLOOC**. HORIZON-KDT-JU-2023-1-IA-Topic-1 — General according to ECS-SRIA 2022 (IA) Type of Action: **HORIZON JU Innovation Actions**. Proposal number: 101132028. 02/24-02/27. Coordinator: Juho Vuononvirta Microfluidic Chipshop GMBH. MJV PI Partner at CIPF
8. **Unidad de Biomodelos CIPF**. Unidades de Plataformas ISCIII de apoyo a la I+D+I en Biomedicina y Ciencias de la Salud de la Acción Estratégica en Salud 2021-2023. Ref. PT23/0017. PI: MJVicent 2023-2025
9. **HERA**. Hydrogels as tools for the development of Long-term release antiemetics. Public-private collaborative projects. AEI. Plan de Recuperación, Transformación y Resiliencia. Ref. CPP2022-010119. Laboratorios Rovi : CIPF. PI: MJ Vicent 01/12/23- 30/09/26.
10. **IMPULSE**. IMProving User experience, Long-term sustainability and Services of EU-OPENSREEN. HORIZON-INFRA-2023-DEV-01-03 Type of Action: **HORIZON-RIA**. Proposal number: 101132028. 10/23-10/26. Coordinator: UE-OS. MJV Partner CIPF screening Site
11. **AORG2023**. VI RSEQ Chemical Biology Group Meeting- ChemBioVI. Generalitat Valenciana **CIAORG/2022/026** Valencia 6-8 March 2023. PI: María J Vicent
12. **Cells2Spine**: Spatial Transcriptomics and Cell Communication Models applied to tissue regeneration and treatment in Spinal Cord Injury with Precision Nanomedicine. Prometeo Program CIPROM/2022/25. Generalitat Valenciana, 09/23-09/27. Coordinator: Ana Conesa (CSIC)
13. **Pol@Mets**. Polypeptidic Multimodal Precision Nanoplatfom Nanoplatfom for monitorization and treatment of metastatic tumors. Ref. MFA/2022/065. Materials Program i+d+i. 01/10/2022 - 30/09/2025. PRINCIPAL INVESTIGATOR: Dr. M. J. Vicent.
14. **CanServ**. Providing cutting edge cancer research services across Europe. **HORIZON-INFRA-2021-SERV-01**. Grant agreement ID: 101058620. 01/09/2022 - 31/08/2025. Coordinator: BBMRI-ERIC. MJV Partner through EU-Openscreen
15. Beca Santiago **Grisolía** FUNDING AGENCY: Conselleria d'Educació. Generalitat Valenciana (CIGRIS/2021/100) LENGTH: 16/09/2022 - 15/09/2026. PRINCIPAL INVESTIGATOR: Dr. M. J. Vicent.
16. New Nanotechnological therapy for Parkinson's disease: Nose to brain delivery of GBA-polymer nanoconjugates (**NanoGBA-HR22-00602**). FUNDING AGENCY: **Health Foundation La Caixa**. LENGTH: 1/10/2022-30/09/2025. Coordinator: M Martínez-Vicente (VHIR, Barcelona), PI: MJ Vicent, J Lorenzo
17. **MULTISMART**-Multi-component Soft Materials Advanced Research Training Network. HORIZON-MSCA-2021-DN-01-01 Project ID 101072585. 101072585. Coordinator André Del Guerzo (univ Bordeaux, France). (MJVicent Partner at CIPF). 01/01/2023-31/12/2026.
18. **POLYBRAINT**-Versatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders. FUNDING AGENCY: **ERC-2022-PoC-101069391**. LENGTH: 01/04/2022 to 30/11/2023 PI: Dr. María J. Vicent.
19. Research for a new Vaccine for Human respiratory Disease. CDTI Misiones. Ref Nº 00146282/MIG-20211034, Acronym: **VSRVAC**. Type of Contract: Research and Development. Company: HIPRA and PTS SL. 2021-2023
20. New Therapeutic approaches to Achondroplasia. **Marató TV3**. PI: M. Angela Nieto. 01/01/2021 - 31/12/2023. MJV team member
21. Synergistic Approach for Metastatic Tumor and Neurodegenerative Disorder Treatments using Versatile PolyPeptide-based Conjugates (**SynVerPPC** - Ref PID2019-108806RB-I00) MICINN Plan Nacional I+D 2019. LENGTH: 01/06/2020-29/02/2024 PIs: MJ Vicent.

22. Sensitizing pancreatic cancer to immunotherapy with multimodal precision nanomedicines (**NanoPanTher-HR18-00589**). FUNDING AGENCY: **Health Foundation La Caixa**. LENGTH: 1/11/2019-30/10/2022. Coordinator: MJ Vicent, PI: H Florindo, R. Satchi-Fainaro
23. **BIOMOLMACS**: Molecular Machines Functioning in Cells (**H2020-MSCA-ITN-2019**. Proposal n. 850418) Funding Agency: H2020. LENGTH: 2020-2022. PIs: Coordinator: R. Bezer (Univ Warwick, UK) MJVicent Partner at CIPF.
24. Pharmacological Validation in vivo of nanopharmaceutics inhibitors of ROCK2 in metastatic breast cancer and spinal cord injury (**INNVAL10/19/0467**). Funding Agency: Valencian Agency of Innovation. Length: 2019-2020. PIs: M. J. Vicent
25. Identification of new biomarkers and development of combination nanoconjugates for metastatic prostate cancer treatment. FUNDING AGENCY: **ASEICA**. Length: 2018-2020. PIs: M. J. Vicent
26. Spanish network of Excellence on Extracellular Vesicles. **TENTACLES**. FUNDING AGENCY: Ministerio de Educación, Política Social y Deporte. SAF2018-REDT LENGTH FROM: 01/01/2019-31/12/2021 PI: Dr. María Yañez-Mó. (CBM, Madrid)
27. Off-the-Shelf Polypeptide-based Immunotherapy for Advanced Melanoma Treatment. FUNDING AGENCY: **ERC-2018-PoC DL2 2018-825798-POLYIMMUNE**. LENGTH: 01/01/2018 to 30/09/2020 PIs: Dr. María J. Vicent.
28. Ensuring long-term sustainability of excellence in chemical biology within Europe and beyond- **EU-OPENSREEN-DRIVE**. FUNDING AGENCY: **H2020- INFRADEV-03-2018-2019** Proposal number: SEP-210496506. PRINCIPAL INVESTIGATORS: Philip Gribbon (Univ. Berlin, Germany). LENGTH: 2019-2022
29. Desarrollo de terapias tópicas basadas en sistemas de transporte polipeptídicos. FUNDING AGENCY: **RETOS investigación-PolypepSkin**. MICINN. LENGTH: 2018-2022. Ref. RTC-2017-6465-1. Coordinator: Polypeptide Therapeutic Solutions SL. MJV Academic partner at CIPF.
30. Desarrollo de una plataforma de terapia génica para enfermedades genéticas renales, FUNDING AGENCY: **RETOS investigación**. MICINN. LENGTH: 2018-2022. Ref. RTC-2017-6600-1. Coordinator: ViralGen Vector Core SL. MJV Academic partner at CIPF.
31. Tractament combinatori de les cèl·lules precursors neurals i un nou nanoconjugat de fasudil per a la l'aplicació clínica en lesió aguda de la medul·la espinal. FUNDING AGENCY: **Marató TV3**. LENGTH: 01/03/2018-28/02/2021. PIs: Ferran Pellicé-Maria J. Vicent. (Vall d'Hebron Hospital and CIPF).
32. Estrategia híbrida basada en el cateterismo y la conjugación polimérica del ácido docosahexaenoico para la prevención del daño miocárdico inducido por reperfusión (**PREMICAT-DHA**). FUNDING AGENCY: ISCIII. DTS2017/00067. LENGTH FROM: 2018-2020. PIs: P. Sepúlveda, M. J. Vicent.
33. Beca Santiago **Grisolía** FUNDING AGENCY: Conselleria d'educació. Generalitat Valenciana (GRIOLIA2014/134) LENGTH: 01/07/2014 - 30/06/2016. PI: Dr. M. J. Vicent.
34. Desarrollo de un kit universal para liberación remota controlada de fármacos mediante hipertermia magnética en aplicaciones oncológicas (**INNPACTO IPT-2012-0712-010000**). LENGTH: 2012-2015. PI: N. Cassinelli - WP2 leader M. J. Vicent.
35. Polímeros Terapéuticos diseñados para cruzar la Barrera Hematoencefálica en el tratamiento de desordenes neurodegenerativos- Explorando la Ruta Intranasal. FUNDING AGENCY: Plan Nacional I+D. Ref. **SAF2016-80427-R**. MINECO. LENGTH FROM: Jan 2017 to Dec 2019. PI: Dr. M. J. Vicent.
36. Identificación De Biotipos Moleculares De Cáncer De Próstata Como Base De Una Medicina De Precisión. Acronym: BIOChiP. FUNDING AGENCY: Generalitat Valenciana. Ayudas I+D Para Grupos De Investigación De Excelencia Ref. **PROMETEO/2016/103**. Coordinator: Dr J.A. López-Guerrero (FIVO). (Dr Vicent PI at CIPF)
37. Design of polyPEptide diblock copolymers as macroemulsifiers to produce safe, controlled and reliable novel smart nanoCAPSules with triggered release of active ingredients for skin care applications. Acronym: **PeptiCaps**. FUNDING AGENCY: **H2020 NMP-06-2015**: Novel Nanomatrices and Nanocapsules. LENGTH FROM: 16/11/2015-15/11/2018. COORDINATOR: Damien Dupin. (Dr Vicent as Polypeptide Therapeutic Solutions SL).
38. Developing a strategy for prevention of ischaemia reperfusion injury based on the use of new generation catheters and polymer therapeutics. Acronym: **PREMICAT**. FUNDING AGENCY: Instituto de Salud Carlos III. DTS2015/00083. LENGTH FROM: 04/01/2016-03/01/2018. PRINCIPAL INVESTIGATOR: Dr. María J. Vicent and Pilar Sepúlveda. (IISLa Fe and CIPF).
39. Red española de excelencia de Descubrimiento de Fármacos. **REDEFAR I and II**. FUNDING AGENCY: Ministerio de Educación, Política Social y Deporte. SAF2015-71892-REDT and SAF2017-90913-REDT LENGTH FROM: 01/01/2016-31/12/2019 PRINCIPAL INVESTIGATOR: Dr. Mabel Loza. (Univ. Santiago de Compostela)
40. PRostate cancer biOTypes towards a personalized Medicine: targeting the Igf1r pathway using polymer therapeutics (PROMIse). FUNDING AGENCY: Spanish Oncology Genito Urinary Group Fellowship (**SOGUG**) LENGTH FROM: 01/07/2015-30/06/2017 PRINCIPAL INVESTIGATOR: Dr. Miguel Angel Climent. (FIVO and CIPF).

41. Designing Personalised Polymer-based Combination Nanomedicines for Advanced Stage Cancer Patients. Acronym: **MyNano**. FUNDING AGENCY: **ERC Consolidator Grant** 2014 (Ref: Ares(2015)340043 - ERC-2014-CoG - 648831). 01/07/2015 to 31/12/2020 PRINCIPAL INVESTIGATOR: Dr. María J. Vicent.
42. Polímeros Terapéuticos como agentes simples y en combinación para el tratamiento de cáncer y neurodegeneración. FUNDING AGENCY: Plan Nacional I+D. Ref. **SAF2013-44848-R**. MINECO. LENGTH FROM Jan 2014 to Dec 2016. PRINCIPAL INVESTIGATOR: Dr. María J. Vicent.
43. Desarrollo de nanofármacos de combinación para cáncer de mama triple negativo. FUNDING AGENCY: Fundación Sandra Ibarra. Feb 2016 to Feb 2018. PI: Dr. María J. Vicent.
44. Desarrollo de un kit universal para liberación remota controlada de fármacos mediante hipertermia magnética en aplicaciones oncológicas (**INNPACTO** IPT-2012-0712-010000). LENGTH: 2012-2015. PRINCIPAL INVESTIGATOR: N. Cassinelli - WP2 leader M. J. Vicent.
45. Novel Polymer conjugates with Dual Release FUNDING AGENCY: Royal Society. International Exchange Grant. 2012/R2 Jan 2013 TO Dec 2014 PRINCIPAL INVESTIGATOR: Dr Paul & Dr. Vicent
46. Polymeric nanopharmaceuticals as single agents and in combination therapy. FUNDING AGENCY: MICINN Plan nacional I+D (**CTQ2010-18195/BQU**) Jan 2011 TO Dec 2013 PI: Dr. María J. Vicent
47. Self-Assembling Therapeutics for Specific Nanoscale Interactions with the Sodium Pump. ACRONYM: INANONAK. (Interfacing Advanced NANOconjugates and the Na⁺/K⁺-ATPase (the sodium pump)) FINANCIAL ENTITY: **NanoSci-E+**. Transnational Call for Collaborative Proposals (2008) Acción Complementaria Euro Investigación (EUI2008-03905) Sept 2009 To Jan 2013 PARTICIPANTS 4 groups COORDINATOR: Dr María J. Vicent
48. Light-based functional in vivo monitoring of diseases related enzymes ACRONYM: LIVIMODEFINANCIAL ENTITY: **FP7-HEALTH-2009**-single-stage. Collaborative project. Project nº. 241919. Nov 2009 To May 2013 PARTICIPANTS: 10 research groups COORDINATOR: Prof. Boris Turk ROLE: WP2 Leader
49. Effect of Polymer Nature and Architecture on Body Fate FINANCIAL ENTITY: **ERA-CHEMISTRY** Transnational Call for Collaborative Proposals (2008). Acción Complementaria Euro Investigación (EUI2008-03904) Oct 2009 TO Oct 2012 PARTICIPANTS: 2 research groups COORDINATOR: Dr M.J. Vicent
50. Nanoconjugados de combinación para el tratamiento de tumores de mama metastáticos y/o quimioresistentes. Fundación **GentxGent** LENGHT Nov 2009- Nov 2011 PRINCIPAL INVESTIGATOR: Dr María J. Vicent
51. Preparación propuesta consorcio europeo **NANO-AS (NMP-2009-4.4.0-1)** in FP7-Health program. MICINN. Acciones complementarias (MAT2008-05020). 2008-2009 PRINCIPAL INVESTIGATOR: Dr María J. Vicent
52. Validación de inhibidores de apoptosis como agentes preservantes de órganos en transplante renal. Fundación Renal Tomás Osma. 2009-2011 PI: Prof. E. Pérez-Payá
53. Rational Design, Synthesis and Evaluation of Polymeric Nanomedicines Modulators of Cellular Apoptosis. MICINN. PLAN NACIONAL I+D (**CTQ2007-60601/BQU**). 2007-2010 PRINCIPAL INVESTIGATOR: Dr María J. Vicent
54. Towards Novel Polymeric Nanomedicines Inhibitors of Cellular Apoptosis. MICINN, Programa Ramón y Cajal (**RYC-2006-002438**) LENGHT FROM: 2007- 2011 PI: Dr María J. Vicent
55. Desarrollo de Nanomedicinas Poliméricas Moduladores de Apoptosis Celular. GVA (**GV07/070**) 2007- 2008 PI: Dr María J. Vicent

Selected Main Contracts with Industry

1. Biological evaluation in vitro and in vivo of non-viral vectors. Type of Contract: Research and Development. Company/Financial entity: PTS SL. Now Curapath *2017-present*
2. Biological evaluation in vivo of non-viral vectors with liver tropism. Type of Contract: Research and Development. Company/Financial entity: Tyrus Therapeutics SL. *2021-2022*.
3. Time to move. A convergent therapeutic approach towards Spinal Cord Injury treatment. R&D. Fund. Step by Step Barcelona, Spain. *2016-2020*.
4. Polymer Conjugates for the treatment of Dry eye. Salvat Laboratories. *2016-2018*.
5. Design of lytic nanomedicines for lung cancer. Type of Contract: Research and Development Company/Financial entity: CGB Lytimval Biotech SL. *2017-2019*.
6. Polymer-based combination conjugates for the treatment of NSCLC Type of Contract: Research and Development. Company/Financial entity: University Malaya. *2016-2018*.
7. Novel approaches for dermocosmetics Type of Contract: Consulting Company/Financial entity: Yegane Investigación. *2018*.

Peer-reviewed Publications (* Corresponding author)

Summary. 162 articles, reviews, and book chapters. Includes: Science Advances, Adv Materials, Angew. Chem (2005 with > 250 citations), Biomaterials (1 with > 150 citations), Adv. Funct. Mat., J. Control Rel, Polymer Chem., and reviews in high impact factor journals including Adv. Drug Deliv. Rev (1 with >800 citations), Curr. Opin. Biotechnol. (>150

citations), 1 Med Res Rev, 1 Trends Biotechnol. (> 600 citations). Of these, we highlight 10 papers - Angew. Chem. (Issue 26, 2005 front piece), 2 papers in Polymer Chemistry (Issue 9 2011 hot paper and 2013 Inside Front Cover), Macromol. Rapid Comm. (Issue 17 2010 back cover), Biomaterials Science (Issue 10, 2015 back cover), 2 in Macromol. Biosci. (2016 and 2017 Back Cover), Advanced Materials (Issue 39, 2017 Front Cover), Wires: Nanomed Nanobiotechnol (Issue 11, 2018, Inside Cover Page) Nanoscale (Issue 12, 2020 Back Cover), Adv Drug Deliv Rev (Issue 160, 2021, Cover), J Control Rel (Issue 332, 2021, Cover Page). Over 90% articles in Q1.

1. I. Conejos-Sánchez, J.J. Arroyo-Crespo, D. Morelló-Bolumar, S. Stifano, V.J. Nebot, **M. J. Vicent***. Diffusion-Ordered NMR Spectroscopy for the In-vitro Monitoring of Polymer Degradation: A Focus on Polypeptides *Analytical Chemistry* **2025 In revision**
2. A Benaicha-Fernández, T Randelović, A Armiñán, V Sebastián, M Fuentes, C Huck-Iriart, E Masiá, P Carrascosa-Marco, P Juanes-Velasco, S Đorđević, C Bayona, I Ochoa, M Medel*, I Conejos-Sánchez*, **M.J. Vicent*** Zinc Phthalocyanine-based Polypeptide Nanocarriers Supporting Multimodal Tumor Treatment *Advanced Materials* **2025 In Revision**
3. I. Conejos-Sánchez*, T. Melnyk, E. Masiá, D. Morelló-Bolumar, L. Tortajada-Comeche, I. Dolz-Pérez, L. I. Torrijos-Saiz, P. Tenhaeff, J. Roos, A. Moruzzi, G. Sogorb, M. Medel, P. Loskill, E. Roselló, V. Sebastian, H. Florindo, C. Felipe-León, V. J. Nebot, V. Herranz-Pérez, J. M. García-Vedugo, **M. J. Vicent***. NanoInBrain: A Rationally Designed Polypeptide-based Hybrid Platform for Targeted Intranasal Brain Drug Delivery *Biomaterials* **2025** 328, 123867
4. A. Serrano-Martí, A. Armiñán*, I. Conejos-Sánchez, D. Mittermüller, S-W Li, P. Tenhaeff, E. Roselló-Sastre, M. Gunzer, H. Cabral, **M.J. Vicent*** Characterization and validation of a bone metastatic prostate cancer model as a nanomedicine evaluation platform *Theranostics*. **2025** doi:10.7150/thno.123005; in press
5. AM López-Estévez, MG Portela, L Piñeiro-Alonso, R Castillo-González, L Sancho-Temiño, N Gómez-Lado, J Codesido, X García-Otero, M Medel, MJ Vicent, M Castellanos, P Aguiar Fernández, L Fernández-Messina, MJ Fernández-Aceñero, A Cruz-Adalia, MJ Alonso. Nanoassemblies for oral protein delivery — The case of monoclonals for inflammatory bowel disease. *J. Control Release* **2025**, 114455. doi: 10.1016/j.jconrel.2025.114455
6. A. Benaicha-Fernández, S. P Atkinson, I. Conejos-Sánchez, M. Medel*, **M. J Vicent***. Polymer-based nanomedicines: Supporting multimodal approaches to glioblastoma multiforme treatment *Advanced Drug Delivery Reviews* **2025**, 115735 Doi: 10.1016/j.addr.2025.115735
7. P. Boix-Montesinos, P. Carrascosa, A. Armiñán*, **M. J. Vicent*** Identification of Functional Biomarkers for Personalized Nanomedicine in Advanced Breast Cancer Models. *Journal of Controlled Release* **2025** 12:113584. doi: 10.1016/j.jconrel.2025.113584
8. L IF Moura, A Malfanti, AI Matos, C Peres, A Armiñán, A Duro-Castaño, I Conejos-Sánchez, M Medel, S Đorđević, P Carrascosa, B Carreira, R Acúrcio, H Xavier-Ferreira, A Hernández-Barranco, E Castellano, E Roselló, J C. Machado, H Peinado, **M.J. Vicent***, H.F. Florindo*. Off-the-shelf multivalent nanoconjugate vaccine rescues host immune response against melanoma. *Advanced Materials*. **2025** DOI:10.1002/adma.202417348.
9. C. Pegoraro, E. Karpova, Y Qutbuddin, E. Masiá, P. Dimitrijevs, C Huck-Iriart, S Gavrilović, P Arsenyan, P Schwille, C Felipe-León, A Duro-Castaño, I. Conejos-Sánchez*, **M. J. Vicent*** Multifunctional Polyproline-polyornithine diblock copolymers with inherent mitochondria tropism. *Advanced Materials* **2025**, 2411595. DOI: 10.1002/adma.202411595
10. C. Pegoraro, A. Guinart, E. Masiá, D. Doellerer, M. C. A. Stuart, I. Conejos-Sánchez*, B. L. Feringa*, **M. J. Vicent*** A Light-driven Molecular Motor-Polypeptide Conjugate Supports Controlled Cell Uptake. *J. Mat Chem B* **2025**. DOI: 10.1039/D4TB02434F
11. C. Pegoraro, E. Masiá, S. Đorđević, C. Huck-Iriart, L. Herrera, S. Esteban-Pérez, I. Conejos-Sánchez*, **M. J. Vicent*** Multifunctional Polypeptide-Based Nanoconjugates for Targeted Mitochondrial Delivery and Non-Viral Gene Therapy. *Chemistry of Materials* **2025**. DOI:10.1021/acs.chemmater.4c02742
12. M. Etxebeeste-Mitxelorena, H. Flores-Romero, S. Ramos-Inza, E. Masiá, M. Nenchova, J. Montesinos, L. Martínez-González, G. Porras, M. Orzáez, **M. J. Vicent***, C. Gil, E. Area-Gomez, A. Garcia-Saez, A. Martínez* Modulation of mitochondria-endoplasmic reticulum contacts (MERCs) by small molecules as a new strategy for restoring lipid metabolism in amyotrophic lateral sclerosis models. *J. Med. Chem.* **2025**, 68(2), 1179-1194
13. P. Boix-Montesinos, M. Medel, A. Malfanti, S. Đorđević, E. Masiá, D. Charbonnier, P. Carrascosa-Marco, A. Armiñán*, **M. J Vicent*** Rational design of a poly-L-glutamic acid-based combination conjugate for hormone-responsive breast cancer treatment. *J. Control Rel.* **2024**, 375, 193-208
14. O. Zagorodko*, T. Melnyk, **M.J. Vicent***. Morphology evolution of supramolecular aggregates from C3-symmetric peptide amphiphiles. *J. Mol. Liquids J* **2024**, 410, 125664.
15. Z. Andreu*, M. R. Hidalgo, E. Masiá, S. Romera-Giner, P. Malmierca-Merlo, J. A. López-Guerrero, F. García-García*, **M. J. Vicent*** Comparative profiling of whole-cell and exosome samples reveals protein signatures that stratify breast cancer subtypes *Cell. Molecular Life Science*. **2024**, 81:363 <https://doi.org/10.1007/s00018-024-05403-z>

- 16.C. Fante, **M.J. Vicent**, F. Greco. *Chapter 6: Polymer-drug Conjugates in: 'Fundamentals of Pharmaceutical Nanoscience' 2nd Edition*. ISBN978-3-031-59477-9. **2024**. Springer Nature.
- 17.López-Estévez AM, Zhang Y, Medel M, Arriaga I, Sanjurjo L, Huck-Iriart C, Abrescia NGA, **Vicent MJ**, Ouyang D, Torres D, Alonso MJ. Engineering Hyaluronic Acid-based Nanoassemblies for Monoclonal Antibody Delivery - Design, Characterization, and Biological Insights. *Nano Research*, **2024**, 17, 9111–9125.
- 18.C. Pegoraro, I. Domingo, I. Conejos-Sánchez*, **M.J. Vicent***. Unlocking the mitochondria for nanomedicine-based Treatments: Overcoming biological Barriers, improving Designs, and selecting *Adv. Drug Deliv. Rev.* **2024**, 115195.
- 19.S. Dordevic, M. Medel, J.Hillaert, E. Masià, I. Conejos-Sánchez*, M.J. Vicent*. Critical Design Strategies Supporting Optimized Drug Release from Polymer-Drug Conjugates. *Small* **2024** 20(4), 2303157
- 20.I. Domingo, P. Ferrer-Torres, A. Armiñan, **M.J. Vicent***, A. Pineda-Lucena*, M. Palomino-Schwartzlein*, NMR-based mitochondria metabolomic profiling: a new approach to reveal cancer-associated alterations *Analytical Chemistry* **2023** 95(45), pp. 16539–16548
- 21.O. Zagorodko*, T. Melnyk, V.J. Nebot, P. Y. W. Dankers, **M. J. Vicent***. 2D assemblies from C3-symmetric peptide amphiphiles have unconventional parallel cross- β -supersecondary structure. *Chemistry A European Journal* **2023**. 10.1002/chem.202303194
- 22.S. Vicente-Ruiz, A. Armiñan*, K. Maso, O. Zagorodko, E. Gallon, F. Rodriguez-Otormín, J. Movellan, M. Baues, J. May, F. De Lorenzi, T. Lammers, **M.J. Vicent*** Poly-L-Glutamic Acid Modification Modulates the Bio-nano Interface of a Therapeutic Anti-IGF-R1 Antibody in Prostate Cancer. *Biomaterials* **2023** 301, 122280
- 23.J.A. López-Guerrero, M. Valés-Gómez, F. E. Borrás, J. M. Falcón-Pérez, **M. J. Vicent**, M. Yáñez-Mó. Standardizing the Preanalytical Reporting of Biospecimens to Improve Reproducibility in Extracellular Vesicle Research - A GEIVEX Study". *Journal of Extracellular Biology* **2023** DOI: 10.1002/jex2.76
- 24.T. Melnyk, E. Masià, O. Zagorodko, I. Conejos-Sánchez*, **M.J. Vicent***. Rational Design of Poly-L-glutamic acid-Palbociclib Conjugates for Pediatric Glioma Treatment. *J. Controlled Rel.* **2023**, 355,385-394
- 25.Z. Andreu*, E. Masià, D. Charbonnier, **M.J. Vicent*** A Rapid, Convergent Approach to the Identification of Exosome Inhibitors in Breast Cancer Models. *Nanotheranostics*, **2023**, 7(1), 1-21.
- 26.E. Giraldo, P. Bonilla, M. Mellado Lopez, P. Garcia Manau, C. Rodriguez, A. Alastrue, E. Lopez Mocholi, E. Carreras, F. Pellisé, S. Dordevic, **M. J. Vicent**, V. Moreno Manzano. Transplantation of Human Fetal Spinal cord-derived NPCs Primed with a Polyglutamate-conjugated Rho/Rock Inhibitor as a Therapy for Acute Spinal Cord Injury. *Cells*, **2022**, 11(20), 3304
- 27.A. Lepland , A. Malfanti, U. Haljasorg, E. K. Ascitto, M. Pickholz, M. Bringas, S. Đorđević, L. Salumäe, P. Peterson, T. Teesalu*; **M. J. Vicent***, P. Scodeller* Depletion of Mannose Receptor-Positive Tumor-Associated Macrophages via a Peptide-Targeted Star-Shaped Polyglutamate Inhibits Breast Cancer Progression in Mice. *Cancer Res Comm.* **2022**, 2(6), 533-551
- 28.Satchi-Fainaro R, Florindo HF, **Vicent MJ*** Clinically-relevant and predictive cancer models for nanomedicine evaluation. Special Issue. *Adv. Drug Deliv. Rev.* **2022**, 183, 114140.
- 29.H. N. Geo, D. D. Murugan, Z.Chik, A.Norazit, Y.Y. Foo, B. F.Leo, Y. Y. Teo, S.Z.S.B.S.A. Kadir, Y. Chan, H. J. Chai, M. Medel, N.A. Abdullah, E.J. Johns, **M.J. Vicent***, L. Y. Chung, L. V. Kiew*. Renal Nano-drug delivery for acute kidney Injury: Current status and future perspectives. *J. Control Release* **2022**, 343, 237-254.
- 30.L. Tortajada-Comeche, C. Felip*, **M.J. Vicent***. Polymer-based Non-viral Vectors for Gene Therapy in the Skin. *Polymer Chemistry*. **2022**, 13 (6), 718-735
- 31.Y. Fernández, J. Movellan, L. Foradada, V. Giménez, N. Garcv#a-Aranda, S. Mancilla, A. Armiñan, S. E. Borgos, A. Hyldbakk, A. Bogdanska, O.L. Gobbo, A. Prina-Mello, O. Zagorodko, E. Gallon, A. Niño-Pariente, A. Paul, S. Schwartz Jr., I. Abasolo*, **M.J. Vicent.*** In vivo anti-tumor and metastatic efficacy of a polyacetal-based paclitaxel conjugate for prostate cancer therapy. *Adv. Healthcare Mat.* **2022**, 11(7) 2101544
- 32.H. Elkhany, P. Bonilla, E. Giraldo, A. Alastrue Agudo, M.I Edel, **M. J. Vicent**, F. Gisbert Roca, L. Rodríguez Doblado, C. Martínez-Ramos, M. Monleón Pradas, V. Moreno-Manzano. A Hyaluronic Acid Demilune Scaffold and Polypyrrole-coated Fibers Carrying Embedded Human Neural Precursor Cells and Curcumin for Surface Capping of Spinal Cord Injuries. *Biomedicines*. **2021**, 9, 1928
- 33.Gómez-Cebrián, N., I. Domingo-Ortí, J. L. Poveda, **MJ. Vicent**, L. Puchades-Carrasco and A. Pineda-Lucena. Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments. *Cancers (Basel)*, **2021**;13:18
- 34.P. M Soriano-Teruel, G.o García-Laínez, M. Marco-Salvador, J. Pardo, M. Arias, C. De Ford, I. Merfort, **M. J Vicent**, P. Pelegrin, M. Sancho, M. Orzáez. Identification of an ASC Oligomerization Inhibitor for the Treatment of Inflammatory Diseases. *Cell Death & Disease*. **2021**, 12(12), 1-11
- 35.F.J. Sanz, C Solana-Manrique, J Torres, E Masià, MJ Vicent, N Paricio. A high-throughput chemical screen in DJ-1 β mutant flies identifies zaprinast as a potential Parkinson's disease treatment. *Neurotherapeutics.*, **2021**. 18(4):2565-2578.

36. Conejos-Sánchez I., Dordevic S., Medel M.*, **Vicent MJ.*** Polypeptides as building blocks towards functional nanotheranostics. *Current Opinion in Biomedical Engineering*. **2021**, 20:100323
37. E. Giraldo, V. Nebot, O. Zagorodko, Raquel Requejo-Aguilar, A. Alastrue-Agudo, A. Armiñan, B. Martinez-Rojas, Pablo Bonilla-Villamil, S Dordevic, **M.J. Vicent***, V. Moreno-Manzano* A rationally designed self-immolative linker enhances the synergism between a polymer-rock inhibitor conjugate and neural progenitor cells in the treatment of spinal cord injury. *Biomaterials* **2021**, 276, 121052
38. Dordevic S., Medel M, Conejos-Sánchez I., Carreira; B., Pozzi P., Acúrcio R., Satchi-Fainaro R.*, Florindo H.F.*, **Vicent M.J.***. Current Hurdles to the Translation of Nanomedicine from Bench to the Clinic. *Drug Delivery and Translational Research*. **2021**, 1-26
39. P. Bonilla, J. Hernandez, E. Giraldo, M.I.Á. González-Pérez, A. Alastrue-Agudo, H. Elkhenany, **M. J. Vicent**, X. Navarro, M. Edel, V. MorenoManzano. Human Induced Neural and Mesenchymal Stem Cell Therapy Combined with A Curcumin Nanoconjugate as a Spinal Cord Injury Treatment. *Int. J. Mol. Sci* **2021**, 22(11):5966
40. Zagorodko, T Melnyk, O Rogier, VJ Nebot*, **MJ Vicent.*** Higher-order interfiber interactions in the self-assembly of Benzene-1,3,5-tricarboxamide-based peptides in water. *Polymer Chemistry*. **2021**, d1py00304f.
41. CM Cuesta CM, F, Ibañez, R Lopez-Hidalgo, J. Ureña, A. Duro-Castano, A. Armiñán, **M.J. Vicent**, M. Pascual, C. Guerri. A Targeted Polypeptide-based Nanoconjugate as a Nanotherapeutic for Alcohol-induced Neuroinflammation. *Nanomedicine:NBM* **2021**, 102376.
42. A Duro-Castano, A Sousa-Herves, A Armiñán, D Charbonnier, JJ Arroyo-Crespo, S Wedepohl, M Calderón*, **M.J. Vicent*** Polyglutamic acid-based Crosslinked Doxorubicin Nanogels as Anti-Metastatic Treatment for Triple Negative Breast Cancer. *J. Control. Rel.* **2021**, 332, 10-20. Cover Page.
43. S Tejedor, I Dolz-Pérez, C G. Decker, A Hernández, J L. Diez, R Álvarez, D Castellano, NA. García, I Ontoria-Oviedo, VJ. Nebot, H González-King, B Igual, P Sepúlveda*, **MJ. Vicent*** Polymer Conjugation Potentiates Cardioprotective Therapy in Preclinical Models of Myocardial Ischemia/Reperfusion Injury. *Advanced Healthcare Materials* **2021**, 2002121.
44. A. Duro-Castano, C. Borrás, V. Herranz-Pérez, M.C. Blanco-Gandía, I. Conejos-Sánchez, A. Armiñan, C. Mas-Bargues, M. Inglés, J. Miñarro, M. Rodríguez-Arias, J. M. García-Verdugo, J. Viña, **M.J. Vicent*** Targeting Alzheimer's disease with Multimodal Polypeptide-based Nanoconjugates. *Science Advances* **2021**, 7, eabf9180.
45. Boix-Montesinos P., Soriano P., Armiñán A.,* Orzáez M.,* **Vicent M.J.*** The Past, Present, and Future of Breast Cancer Models for Nanomedicine Development. *Advanced Drug Delivery Reviews* **2021**, 173:306-330
46. Yin L*, Chen JJ*, Deming T* and **Vicent MJ***. Co-editors of Synthetic Polypeptides for Drug and Gene Delivery, and Tissue Engineering. *Advanced Drug Delivery Reviews* **2021**.
47. Vicente-Ruiz, S., Serrano-Martín, A., Armiñán, A.*, and **Vicent, M. J***. Nanomedicine for the Treatment of Advanced Prostate Cancer. *Advanced Therapeutics*, **2021**;4: 2000136
48. Silvestri A., Vicente F, **Vicent M.J.**, Stechmann B., Fecke W. Academic collaborative models fostering the translation of physiological in vitro systems from basic research into drug discovery. *Drug Discovery Today* **2021**, 26(6), 1369-1381
49. D Van Lysebetten, A Malfanti, K De Swarte, K Koykov, B Golba, T Ye, Z Zhong, S Kasmi, A Lamoot, Y Chen, S Van Herck, B N. Lambrecht, N N. Sanders, S Lienenklaus, S A David, **M J Vicent**, S De Koker, B G De Geest. Lipid-Polyglutamate Nanoparticle Vaccine Platform *ACS Applied Materials and Interfaces* **2021**, 13, 5, 6011–6022.
50. R. Martí-Centelles, I. Dolz-Pérez, J. De la O, I. Ontoria-Oviedo, P. Sepúlveda, V.J. Nebot*, **M. J. Vicent***, and B. Escuder*. Two-Component Peptidic Molecular Gels for Topical Drug Delivery of Naproxen. *ACS Applied Bio Materials*. **2021**, 4, 1, 935–944
51. A. Lepland, E. Asciutto, A. Malfanti, L. Simón-Gracia, V. Sidorenko, **M.J. Vicent**, T. Teesalu, P. Scodeller. Targeting pro-tumoral macrophages in early primary and metastatic breast tumors with CD206-binding mUNO peptide. *Molecular Pharmaceutics*, **2020**(17)7:2518–2531.
52. Ghandehari, H., H. K. Chan, H. Harashima, J. A. MacKay, T. Minko, K. Schenke-Layland, Y. Shen, and **M. J. Vicent**. Advanced Drug Delivery 2020 – Parts 1, 2, and 3. *Advanced Drug Delivery Reviews*, **2020**;156: 1-2.
53. T. Melnyk, S. Dordevic, I. Conejos-Sánchez*, **MJ. Vicent***. Therapeutic Potential of Polypeptide-Based Conjugates: Rational Design and Analytical Tools That Can Boost Clinical Translation. *Advanced Drug Delivery Reviews* **2020**, 160: 136-169. Cover Page.
54. G. Córdoba-David, A. Duro-Castano, R.C. Castelo-Branco, C. González-Guerrero, P. Cannata, A.B. Sanz, **M.J. Vicent**, A. Ortiz & A.M. Ramos. Effective Nephroprotection Against Acute Kidney Injury with a Star-Shaped Polyglutamate-Curcuminoid Conjugate. *Scientific Reports*, **2020**(10), 2056.
55. O. Zagorodko, V. J. Nebot*, and **M. J. Vicent***. The generation of stabilized supramolecular nanorods from star-shaped polyglutamates. *Polymer Chemistry*, **2020**(11):1220-1229.

56. Dolz-Pérez, I., M. A. Sallam, E. Masiá, D. Morelló-Bolmar, M. D. P. del Caz, P. Graff, D. Abdelmonsif, S. Hedtrich, V. J. Nebot, and **M. J. Vicent***. Polypeptide-corticosteroid conjugates as a topical treatment approach to psoriasis. *Journal of Controlled Release*, **2020**(318):210-222.
57. Conejos-Sánchez, I.*, Gallon, E., Niño-Pariente, A., Smith, J. A., De la Fuente, A. G., DiCanio, L., Pluchino, S., Franklin, R.J.M., **M.J. Vicent***. Polyornithine-based polyplexes to boost effective gene silencing in CNS disorders. *Nanoscale* **2020**(12):6285-6299. *Inside Cover Page*.
58. J.J. Arroyo-Crespo, A. Armiñán*, D. Charbonnier, C. Deladriere, M. Palomino-Schätzlein, R. Lamas-Domingo, J. Forteza, A. Pineda-Lucena, **M.J. Vicent***. Characterization of Triple-Negative Breast Cancer Preclinical Models Provides Functional Evidence of Metastatic Progression. *International Journal of Cancer*, **2019**;145(8):2267-2281.
59. Maso, K., Grigoletto, A., **Vicent, M. J.***, & Pasut, G*. Molecular Platforms for Targeted Drug Delivery. In *International Review of Cell and Molecular Biology: Academic Press*, **2019**.
60. Castaño A, Talelli M, Rodríguez-Escalona G, **Vicent MJ***. Smart Polymeric Carriers for Drug Delivery. In: *Smart Polymers and their Applications*. Chapter 11, Editors: Maria Rosa Aguilar Julio San Román, (2nd Edition.) Woodhead Publishing, **2019**.
61. LIF Moura, A. Malfanti, C. Peres, Al. Matos, E. Guegain, V. Sainz, W. Zloh, **MJ. Vicent***, HF Florindo*. Functionalized Branched Polymers: Promising Immunomodulatory Tools for the Treatment of Cancer and Immune Disorders. *Materials Horizons*, **2019**. 6, 1956-1973
62. **Vicent, MJ*** and Bossard, M*. PEGylated Proteins: A Rationale Design for Mitigating clearance Mechanisms and Altering Biodistribution. In *Polymer-Protein Conjugates (1st Ed.)*. Elsevier. **2019**. Editors: Gianfranco Pasut and Samuel Zalipsky
63. **Vicent, MJ**. Reporter's Comments on "Session Four: Drugs and Genes". In *Definitions of Biomaterials for the Twenty-First Century (1st Edition)*. Elsevier. 21st June **2019**. Editors: Xingdong Zhang and David Williams
64. Brennecke P, Rasina D, Aubi O, Herzog K, Landskron J, Cautain B, Vicente F, Quintana J, Mestres J, Stechmann B, Ellinger B, Brea J, Kolanowski JL, Pilarski R, Orzaez M, Pineda-Lucena A, Laraia L, Nami F, Zielenkiewicz, Paruch K, Hansen E, von Kries JP, Neuenschwander M, Specker E, Bartunek P, Simova S, Lesnikowski Z, Krauss S, Lehtio L, Bilitewski H, Brönstrup M, Tasken K, Jirgensons A, Lickert H, Clausen MH, Andersen JH, **Vicent MJ**, Genilloud O, Martínez A, Nazaré M, Fecke W, Gribbon P. EU-OPENSREEN: A Novel Collaborative Approach to Facilitate Chemical Biology. *SLAS Discovery*, **2019**;7:2472555218816276
65. Armiñán, A., Palomino-Schätzlein, M., Deladriere, C., Arroyo-Crespo, J. J., Vicente-Ruiz, S., **Vicent, M.J.***, and Pineda-Lucena, A.* Metabolomics facilitates the discrimination of the specific anti-cancer effects of free- and polymer-conjugated doxorubicin in breast cancer models. *Biomaterials* **2018**.162: p. 144-153
66. Arroyo-Crespo, J.J., Armiñán, A., Charbonnier, D., Balzano-Nogueira, L., Huertas-López, F., Martí, C., Tarazona, S., Forteza, J., Conesa, A., **Vicent, M.J.***. Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment. *Biomaterials*, **2018**. 186: p8-21.
67. Arroyo-Crespo, J.J., Deladriere, C., Nebot, V.J., Charbonnier, D., Masiá, E., Paul, A., James, C., Armiñán, A.*, **Vicent, M.J.***, Anticancer Activity Driven by Drug Linker Modification in a Polyglutamic Acid-Based Combination-Drug Conjugate. *Advanced Functional Materials*, **2018**. 28(22): p. 1800931
68. Cheah HY, Gallon E, Dumoulin F, Hoe SZ, Japundžić-Žigon N, Glumac S, Lee HB, Anand P, Chung LY, **Vicent MJ***, Kiew LV*. Near-infrared activatable phthalocyanine-poly-L-glutamic acid conjugate: enhanced in vivo safety and antitumor efficacy towards an effective photodynamic cancer therapy. *Molecular Pharmaceutics*, **2018**,15(7): p. 2594–2605.
69. Duro-Castano, A., Lim, N.H., Tranchant, I., Amoura, M., Beau, F., Wieland, H., Kingler, O., Herrmann, M., Nazaré, M., Plettenburg, O., Dive, V.*, **Vicent, M.J.***, and Nagase, H*. In Vivo Imaging of MMP-13 Activity Using a Specific Polymer-FRET Peptide Conjugate Detects Early Osteoarthritis and Inhibitor Efficacy. *Advanced Functional Materials*, **2018**. 28: p1802738.
70. Plyduang, T., Armiñán, A., Movellan, J., England, R.M., Wiwattanapatapee, R., and **Vicent, M.J.***, Polyacetal-Based Combination Therapy for the Treatment of Prostate Cancer. *Macromolecular Rapid Communications*, **2018**. 39: p1800265.
71. F. Rodríguez-Otormin, A. Duro-Castano, I. Conejos-Sánchez*, **MJ Vicent*** Tackling life threatening brain disorders by means of polymer therapeutics. *Wires: Nanomedicine & Nanobiotechnology* **2018**. 11:e1532. *Inside Cover Page*.
72. Atkinson, S.P. Andreu Z, **Vicent MJ*** Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment. *Journal of Personalized Medicine*, **2018**. 8(1): p. 6.
73. Duro-Castano A, Gallon E, Decker C, **Vicent MJ***. Modulating angiogenesis with integrin-targeted nanomedicines. *Advanced Drug Delivery Reviews*, **2017**. 119(Supplement C): p. 101-119.
74. Cheah, H.Y. Kiew LW, Lee HB, Japundzic-Zigon N, **Vicent MJ**, Hoe SZ, Chung LY. Preclinical safety assessments of nano-sized constructs on cardiovascular system toxicity: A case for telemetry. *Journal of Applied Toxicology*, **2017**. 37(11): p. 1268-1285.

75. Zagorodko, O., Arroyo-Crespo JJ, Nebot VJ, **Vicent MJ*** Polypeptide-Based Conjugates as Therapeutics: Opportunities and Challenges. *Macromol Biosci*, **2017**. 17(1). *Inside Cover Page*
76. Duro- Castaño A., Talelli M, Rodríguez-Escalona G, **Vicent MJ***. Smart Polymeric Carriers for Drug Delivery. In: Smart Polymers and their Applications. Chapter 11, J. San Román (2nd Edition.) Woodhead Publishing, **2017**.
77. Satchi-Fainaro, R.* , **Vicent, M.J.***, and Richardson, S.* , *Professor Ruth Duncan: A Pioneer in the Field of Polymer Therapeutics. Journal of Drug Targeting*, **2017**: p. 1-3
78. Escalona, G.R., Sanchis, J., and **Vicent, M.J.*** pH-Responsive Polyacetal–Protein Conjugates Designed for Polymer Masked–Unmasked Protein Therapy (PUMPT). *Macromolecular Bioscience*, **2017**. 2017: p. 1700302-n/a.
79. Duro-Castaño, A., Nebot, V. J.*, Niño-Pariente, A., Armiñán, A., Arroyo-Crespo, J. J., Paul, A., Feiner-Gracia, N., Albertazzi, L. and **Vicent, M.J.*** Capturing Extraordinary Soft-Assembled Charge-Like Polypeptides as a Strategy for Nanocarrier Design. *Advanced Materials*, **2017**. 29(39): p. 1702888-n/a. *Inside Cover Page*.
80. Armiñán, A., Mendes, L., Carrola, J., Movellan, J., **Vicent, M.J.*** and Duarte, I. F.* HIF-1 α inhibition by diethylstilbestrol and its polyacetal conjugate in hypoxic prostate tumour cells: Insights from NMR metabolomics. *J Drug Target*, **2017**. 25(9-10): p. 845-855.
81. Eldar-Boock, A., Blau, R., Ryppa, C., Baabur-Cohen, H., Many, A., **Vicent, M.J.**, Kratz, F., Sanchis, J. and Satchi-Fainaro, R. Integrin-Targeted Nano-Sized Polymeric Systems for Paclitaxel Conjugation: A Comparative Study. *J Drug Target*, **2017**. 25(9-10): p. 829-844.
82. Niño-Pariente, A., Armiñán, A., Reinhard, S., Scholz, C., Wagner, E., **Vicent, M.J.*** Design of Poly-L-Glutamate-Based Complexes for pDNA Delivery. *Macromolecular Bioscience*, **2017**. 17(10): p. 1700029-n/a.
83. Kiew, L.V., Cheah, H.Y., Voon, S.H., Gallon, E., Movellan, J., Ng, K.H., Alpugan, S., Lee, H.B., Dumoulin, F., **Vicent, M.J.***, and Chuehdang, L.Y. Near-Infrared Activatable Phthalocyanine-Poly-L-Glutamic Acid Conjugate: Increased Cellular Uptake and Light-Dark Toxicity Ratio Towards An Effective Photodynamic Cancer Therapy. *Nanomedicine*, **2017**. 13(4): p. 1447-1458.
84. Cheah, H.Y., Sarenac, O., Arroyo, J.J., Vasic, M., Lozic, M., Glumac, S., Hoe, S.Z., Hindmarch, C.C., Murphy, D., Kiew, L.V., Lee, H.B., **Vicent, M.J.**, Chung, L.Y., and Japundzic-Zigon, N., Hemodynamic effects of HPMA copolymer-based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats. *Nanotoxicology*, **2017**. 11(2): p. 210-222.
85. Requejo-Aguilar R, Alastrue-Agudo A, Cases-Villar M, Lopez-Mocholi E, England R, **Vicent MJ***, Moreno-Manzano V.* Combined polymer-curcumin conjugate and ependymal progenitor/stem cell treatment enhances spinal cord injury functional recovery. *Biomaterials* **2017** 113: 18-30.
86. Roncador, A., Oppici, E., Talelli, M., Pariente, A.N., Donini, M., Dusi, S., Voltattorni, C.B., **Vicent, M.J.***, and Cellini, B.* Use of polymer conjugates for the intraperoxisomal delivery of engineered human alanine:glyoxylate aminotransferase as a protein therapy for primary hyperoxaluria type I. *Nanomedicine:NBM*, **2017**. 13(3): p. 897-907.
87. Nino-Pariente, A. Nebot VJ, **Vicent MJ*** Relevant Physicochemical Descriptors of "Soft Nanomedicines" to Bypass Biological Barriers. *Curr Pharm Des*, **2016**. 22(9): p. 1274-91.
88. Duro-Castano, A., Movellan, J., and **Vicent, M.J.***, Smart branched polymer drug conjugates as nano-sized drug delivery systems. *Biomater Sci*, **2015**. 3(10): p. 1321-34. *Inside Cover Page*
89. Monleón M. and **Vicent M.J.** (Book Editors) (2015) Title: Applications of Polymers on Tissue Regeneration and Repair. Wiley-Blackwell. John Wiley & Sons. ISBN:978-0-470-59638-8
90. Armiñán, A, Sepúlveda, P., **Vicent, M.J.*** (2015) Polymer Therapeutics as Nano-Sized Medicines for Tissue Regeneration and Repair In: Polymers in Regenerative Medicine: Biomedical Applications from Nano- to Macro-Structures (Eds. M. Monleón and M.J. Vicent). Chapter 8, pp249-284 Wiley-Blackwell. John Wiley & Sons ISBN:978-0-470-59638-8
91. Duro-Castaño, A., England, R. M., Razola, D., Romero, E., Oteo-Vives, M., Morcillo, M. A. and **Vicent, M.J.*** Well-Defined Star-Shaped Polyglutamates with Improved Pharmacokinetic Profiles as Excellent Candidates for Biomedical Applications. *Mol Pharm* **2015**, 12(10), 3639-3649.
92. Santamaria, B., Uceró, A. C., Benito-Martin, A., **Vicent, M.J.**, Orzáez, M., Celdran, A., Selgas, R., Ruiz-Ortega, M. and Ortiz, A. Biocompatibility reduces inflammation-induced apoptosis in mesothelial cells exposed to peritoneal dialysis fluid. *Blood Purif* **2015**, 39(1-3), 200-209.
93. Conejos-Sánchez, I., Cardoso, I., Oteo-Vives, M., Romero-Sanz, E., Paul, A., Sauri, A.R., Morcillo, M.A., Saraiva, M.J., **Vicent, M.J.***. Polymer-doxycycline conjugates as fibril disrupters: An approach towards the treatment of a rare amyloidotic disease. *J. Controlled Release*. **2015**, 198(1), 80-90
94. Gallon, E., Matini, T., Sasso, L., Mantovani, G., Arminan, A., Sanchis, J., Caliceti, P., Alexander, C.* , **Vicent, M.J.***, Salmaso, S.* Triblock Copolymer Nanovesicles for pH-Responsive Targeted Delivery and Controlled Release of siRNA to Cancer Cells. *Biomacromolecules* **2015**, 16(7), 1924-1937.

95. Casanova-Salas, I., Masia, E., Arminan, A., Calatrava, A., Mancarella, C., Rubio-Briones, J., Scotlandi, K., **Vicent, M.J.*** and Lopez-Guerrero, J. A. * MiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer. *PLoS One* **2015**, 10(5), e0125576.
96. Duro-Castano A. et al. (2014) *Polymers* 6, 515-551
97. Talelli M.* and **Vicent, M.J.*** Reduction sensitive poly(l-glutamic acid) (PGA)-protein conjugates designed for polymer masked-unmasked protein therapy. *Biomacromolecules*. **2014**, 15(11), 4168-4177
98. Conejos-Sánchez, I. Cardoso, M.J. Saraiva, **M.J. Vicent*** Targeting a rare Amyloidotic Disease through Rationally Designed Polymer Conjugates. *J. Controlled Release*. **2014**, 178, 95-100
99. T Matini, S Spain, G Mantovani, **M J. Vicent***, J Sanchis, E Gallon, F Mastrotto, S Salmaso*, P Caliceti, C Alexander* Synthesis and characterization of variable conformation pH responsive block co-polymers for nucleic acid delivery and targeted cell entry. *Polymer Chemistry* **2014**, 5(5), 1626-1636
100. I Casanova-Salas, J Rubio-Briones, A Calatrava, C Mancarella, E Masiá, J Casanova, A Fernández-Serra, L Rubio, M Ramírez-Backhaus, A Armiñán, J Domínguez-Escrig, F Martínez, Z García-Casado, K Scotlandi, **M J. Vicent**, J. A. López-Guerrero. Identification of miR-187 and miR-182 as biomarkers for early diagnosis and prognosis in prostate cancer patients treated with radical prostatectomy. *Journal of Urology*. **2014**, 192(1), 252-259
101. M. Talelli, A. Duro-Castaño, G. Rodríguez-Escalona, **M.J. Vicent***. (2013) Smart Polymeric Carriers for Drug Delivery. In: Smart Polymers and their Applications. Chapter 11. (RM Aguilar and J San Roman, Eds). Woodhead Publishing.
102. M Barz*, A Duro-Castaño, **M.J. Vicent***. A versatile post-polymerization modification method for polyglutamic acid: synthesis of orthogonal reactive polyglutamates and their use in click chemistry. *Polymer Chemistry* **2013**, 4(10), 2980- 2994. *Inside Cover Page*
103. I Conejos-Sánchez, A Duro-Castaño, A. Birke, M Barz*, **M.J. Vicent*** A controlled and versatile NCA polymerization method for the synthesis of polypeptides *Polymer Chemistry* **2013**, 4(11), 3182- 3186.
104. AC. Ucero, S. Berzal, C. Ocaña-Salceda, M Sancho, M Orzáez, **M.J. Vicent**, A Ortiz, AMA Ramos. A Polymeric Nanomedicine Diminishes Inflammatory Events in Renal Tubular Cells. *PLoS ONE* **2013**, 8(1), e51992.
105. SPE Deacon, B Apostolovic, A-K Schott, RJ Carbajo, **MJ Vicent**, A Pineda-Lucena, H-A Klok, R Duncan. Polymer Therapeutics containing coiled-coils: New therapeutics and linkers. *European Cells and Materials*. **2013**, 200(3),66.
106. R. England, E. Masiá, V. Giménez, R. Lucas, **MJ. Vicent***. Polyacetal-Stilbene conjugates- the first examples of polymer therapeutics for the inhibition of HIF-1 in the treatment of solid tumours. *J. Controlled Release* **2012**, 164(3), 314-322.
107. M Barz*, A. Armiñán, F Canal, F Wolf, K Koynov, H Frey, R. Zentel, **MJ Vicent*** P(HPMA)-block- P(LA) copolymers in paclitaxel formulations: Polylactide stereochemistry controls micellization, cellular uptake kinetics, intracellular localization and drug efficiency. *J. Controlled Release*. **2012**, 163(1), 63- 74
108. V. Giménez, C. James, A. Armiñán, A. Paul, **M J. Vicent***. Demonstrating the importance of Polymer-Conjugate Conformation in Solution on its Therapeutic Output: Diethylstilbestrol (DES)-Polyacetals as Model Systems. *Journal of Controlled Release*, **2012**, 159(2) 290-301.
109. R.M. England, I. Conejos-Sánchez, **M.J. Vicent*** (2012) Title: Parenteral Drug Delivery of Polymer Therapeutics In Chapter 8. Nanostructures for overcoming the biological barriers related to parenteral drug delivery. In: Nanostructured Biomaterials for overcoming biological barriers. M.J. Alonso and N. Csaba (Eds.) Royal Society Chemistry ISBN: 978-1849733632. Chapter 8.2.
110. SPE Deacon, B Apostolovic, RJ Carbajo, A-K Schott, K Beck, MJ Vicent, A Pineda-Lucena, H-A Klok, R Duncan. Polymer coiled-coil conjugates - therapeutic "molecular switches". *Biomacromolecules*. **2011**, 12(1),19-27.
111. Fabiana Canal, Joaquin Sanchis, **María J. Vicent*** Polymer-Drug Conjugates as Nano-Sized Medicines. *Current Opinion in Biotechnology* **2011**, 22(6), 894-900.
112. C. Deladriere, R. Lucas, **M.J. Vicent***. (2011) Future trends, challenges and opportunities with polymer-based combination therapy in cancer. En: Drug Delivery in Oncology. From Basic Research to Cancer Therapy (3 volumes). F. Kratz, P. Senter and H. Steinhagen (Eds.) Wiley-VCH, Weinheim. ISBN-13: 978-3-527-32823-9, Volume 3 Chapter 4.
113. Eldar-Book, K. Miller, J. Sanchis, R. Lupu, **M.J. Vicent***, R. Satchi-fainaro* Antiangiogenic polymer therapeutics bearing paclitaxel and RGD peptidomimetics as targeting moieties. *Biomaterials* **2011**, 32(15), 3862-3874.
114. M. Barz, R. Luxenhofer, R. Zentel, **M.J. Vicent**. Well-defined Polymers as Potential Alternatives to PEG: From Structure-Property Relationships to better defined Therapeutics. *Polymer Chemistry*. **2011**, 2 (9) 1900-1918. *Highlighted as Hot Paper*
115. Pérez-Payá E.*, Orzáez M., Mondragón L., Wolan D., Wells J.A., Messeguer A., **Vicent M.J.*** Molecules that Modulate Apaf-1 Activity. *Medicinal Research Reviews*. **2011**, 31(4) 649-675.
116. Sanchis, J., Canal, F., Lucas, R., **Vicent, M.J.*** Polymer-drug conjugates for novel molecular targets. *Nanomedicine*, **2010**, 5 (6), pp. 915-935.

117. Duncan, R.* **Vicent, M.J.*** Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities *Advanced Drug Delivery Reviews*, **2010**, 62 (2), pp. 272-282.
118. Mondragón, L., Orzáez, M., Gortat, A., Sancho, M., Messeguer, A., **Vicent, M.J.**, Pérez-Payá, E. Molecules that bind a central protein component of the apoptosome, Apaf-1, and modulate its activity (**2010**) In: Apoptosome: An Up-and-coming Therapeutical Tool, pp. 75-94.
119. F. Canal, M.J. Vicent*, G. Pasut*, O. Schiavon. Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates *J. Controlled Release* **2010**, 146 (3), 388-399.
120. M. Barz, F. Wolf, F. Canal, K. Koynov, **M.J. Vicent**, H. Frey, R. Zentel. Synthesis, Characterization and Evaluation of P(HPMA)-block-P(LLA) Copolymers: A New Type of Functional Biocompatible Block Copolymer. *Macromolecular Rapid Communications* **2010**, 31(17), 1492-1500. *Back Cover Page*.
121. M. Barz*, F. Canal, K. Koynov, R. Zentel, **M.J. Vicent***. Synthesis and in vitro evaluation of defined HPMA folate conjugates: Targeting the folate receptor mediated cellular for specific uptake. *Biomacromolecules* **2010**, 11(9), 2274- 2282.
122. **MJ Vicent***, L Cascales, RJ Carbajo, N. Cortés, A. Messeguer, E. Pérez Payá* Nanoconjugates as intracorporeal neutralizers of bacterial endotoxins. *Journal Controlled release* **2010**, 142, 277-285
123. **Vicent MJ** and Duncan R co-editors. *Advanced Drug Delivery Reviews*, **2009**, 61 (13)
124. **Vicent, M.J.**, Ringsdorf, H., Duncan, R. Polymer therapeutics: Clinical applications and challenges for development. *Advanced Drug Delivery Reviews*, **2009**, 61 (13), pp. 1117-1120.
125. Greco, F., **Vicent, M.J.*** Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. *Advanced Drug Delivery Reviews*, **2009**, 61 (13), pp. 1203-1213.
126. B. Santamaría, A. Benito-Martin, A. Conrado Ucero, A. Reyero, MJ Vicent, M Orzáez, A. Celdrán, R Selgas, M. Ruíz-Ortega, M. López Cabrera, J. Egido, E. Pérez-Payá, A. Ortiz. A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury. *PLoS ONE* **2009**, 4(8): e6634.
127. Duncan R., Gilbert H., Carbajo R.J., **Vicent M.J.** Polymer Masked-Unmasked Protein Therapy (PUMPT). 1. Bioresponsive dextrin-trypsin and MSH conjugates designed for α -amylase activation. *Biomacromolecules* **2008**, 9(4):1146-54.
128. Mondragón L., Orzáez M., Sanclimens G., Moure A., Armiñán A., Sepúlveda P., Messeguer A., **Vicent M. J.***, Pérez-Payá E.* A systematic analysis of cellular apoptosis with current Apaf-1 Modulators. *J. Med. Chem.* **2008**, 51(3): 521-529.
129. Greco, F.*, **Vicent, M.J.*** Polymer-drug conjugates: Current status and future trends *Frontiers in Bioscience*, **2008**, 13 (7), pp. 2744-2756.
130. **Vicent, M.J.***, Dieudonné, L., Carbajo, R.J., Pineda-Lucena, A. Polymer conjugates as therapeutics: Future trends, challenges and opportunities. *Expert Opinion on Drug Delivery*, **2008**, 5 (5), pp. 593-614.
131. Orzáez, M., Mora, P., Mondragón, L., Pérez-Payá, E., **Vicent, M.J.*** Solid-phase chemistry: A useful tool to discover modulators of protein interactions (2007) *International Journal of Peptide Research and Therapeutics*, 13 (1-2), pp. 281-293.
132. Vicent, M.J., Pérez-Payá, E., Orzáez, M. Discovery of inhibitors of protein-protein interactions from combinatorial libraries. *Current Topics in Medicinal Chemistry*, **2007**, 7 (1), pp. 83-95.
133. **Vicent, M.J.*** Polymer-drug conjugates as modulators of cellular apoptosis. *AAPS Journal*, **2007**, 9 (2), art. no. 22, pp. E200-E207.
134. Paul A.*, **Vicent M.J.***, Duncan R. Probing the Solution Conformation of HPMA-Doxorubicin Conjugates with Small-angle Neutron Scattering. *Biomacromolecules* **2007**, 8(5): 1573-1579.
135. Greco F., Vicent M.J., Gee S., Jones A.T., Gee J., Nicholson R.I., Duncan R. The Mechanism of Enhanced Cytotoxicity of HPMA Copolymer-DOX-AGM in Breast Cancer Cells. *J. Controlled Release*. **2007**, **117**: 28-39.
136. Orzáez M., Mondragón L., Malet G., Sanclimens G., Marzo I., Messeguer A., Pérez-Payá E., **Vicent M. J.*** Conjugation of a Novel Apaf-1 Inhibitor to Cell-Membrane Transporters. Effective Methods to Improve Inhibition of Mitochondria-Mediated Apoptosis. *Peptides*, **2007**, **28**: 958-968.
137. **Vicent M.J.***, Pérez-Payá E.* PGA-aided inhibitors of Apaf-1: An Antiapoptotic Polymeric Nanomedicine. *J. Med. Chem.* **2006**, **49**: 3763-3765.
138. Malet G., Martín A.G., Orzáez M., Vicent M.J, Masip I., Sanclimens G., Mingarro I., Ferrer-Montiel A., Messeguer A., Fearnhead H.O., Pérez-Payá E. Small molecule inhibitors of Apaf-1-related caspase-3/-9 activation that control mitochondrial-dependent apoptosis. *Cell Death Differ.* **2006**, **13**: 1523-1532.
139. **Vicent M. J.**, Mondragon L., Orzaez M., Sanclimens G., Messeguer A., Perez-Paya E. Development of novel Apaf-1 ligands: Chemical inhibitors of cellular apoptosis. *J. Pep. Sci.*, **2006**, **12**: 99S.

140. Altava B., Burguete M. I., García-Verdugo E., Luis S. V., **Vicent M. J.** Functional monolithic resins for the development of enantioselective versatile catalytic minireactors with long-term stability: TADDOL supported systems. *Green Chem.*, **2006**, *8*: 717-726.
141. **Vicent, M.J.**,* Duncan, R.* Polymer conjugates: Nanosized medicines for treating cancer. *Trends in Biotechnology*, **2006**, *24* (1), 39-47.
142. Duncan, R., **Vicent, M.J.**, Greco, F., Nicholson, R.I. Polymer-drug conjugates: Towards a novel approach for the treatment of endocrine-related cancer. *Endocrine-Related Cancer*, **2005**, *12* (SUPPL. 1), S189-S199.
143. **Vicent, M.J.***; Greco, F.; Nicholson, R.I.; Paul, A.; Griffiths, P.C.; Duncan, R. Polymer Therapeutics designed as a Novel Combination Therapy for the Treatment of Hormone-Dependent Cancer. *Angew. Chem. Int. Edit.* **2005**, *44*, 2-6. *Highlighted as Front Piece*
144. Greco, F., **Vicent, M.J.***, Penning, N.A., Nicholson, R.I., Duncan, R.* HPMA copolymer-aminogluthethimide conjugates inhibit aromatase in MCF-7 cell lines. *J. Drug Target.* **2005**, *13*, 459-470.
145. Cecil, A.R.L., Hu, Y.L., **Vicent, M.J.**, Duncan, R., Brown, R.C.D. Total Synthesis and Preliminary Biological Evaluation of cis-Solamin Isomers. *J. Org. Chem.* **2004**, *69*, 3368-3374.
146. **Vicent, M.J.***, Tomlinson, R., Brocchini, S., Duncan, R.* Polyacetal-diethylstilboestrol: a polymeric drug designed for pH-triggered activation. *J. Drug Target.* **2004**, *12*, 491-501.
147. **Vicent, M.J.***, Manzanaro, S., de la Fuente, J.A., Duncan, R.* HPMA copolymer-1,5-diazaanthraquinone Conjugates as Novel Anticancer Therapeutics. *J. Drug Target.* **2004**, *12*, 503-515.
148. Manzanaro, S., **Vicent, M.J.**, Martin, M.J., Salvador-Tormo, N., Perez, J.M., Blanco, M.D., Avendano, C., Menendez, J.C., de la Fuente, J.A. Synthesis and biological evaluation of new 1,5-diazaanthraquinones with cytotoxic activity. *Biorg. Med. Chem.* **2004**, *12*, 6505-6515.
149. Avendano, C., Perez, J.M., Blanco, M.D., de la Fuente, J.A., Manzanaro, S., **Vicent, M.J.**, Martin, M.J., Salvador-Tormo, N., Menendez, J.C. Synthesis and structure-activity relationships of 1,5-diazaanthraquinones as antitumour compounds. *Biorg. Med. Chem. Lett.* **2004**, *14*, 3929-3932.
150. Luis, S.V., Altava, B., Burguete, M.I., Collado, M., Escorihuela, J., García-Verdugo, E., **Vicent, M.J.**, Martens, J. Preparation and Optimization of Polymer-Supported and Amino Alcohol Based Enantioselective Reagents and Catalysts. *Industrial and Engineering Chemistry Research*, **2003**, *42* (24), pp. 5977-5982.
151. Burguete, M.I., Collado, M., Escorihuela, J., Galindo, F., García-Verdugo, E., Luis, S.V., **Vicent, M.J.** Nickel complexes from α -amino amides as efficient catalysts for the enantioselective Et₂Zn addition to benzaldehyde. *Tetrahedron Letters*, **2003**, *44* (36), pp. 6891-6894.
152. Burguete, M.I., Collado, M., García-Verdugo, E., **Vicent, M.J.**, Luis, S.V., Von Keyserling, N.G., Martens, J. Development of small focused libraries of supported amino alcohols as an efficient strategy for the optimization of enantioselective heterogeneous catalysts for the ZnEt₂ addition to benzaldehyde. *Tetrahedron*, **2003**, *59* (10), pp. 1797-1804.
153. Burguete, M.I., Fréchet, J.M.J., García-Verdugo, E., Janco, M., Luis, S.V., Svec, F., **Vicent, M.J.**, Xu, M. New CSPs based on peptidomimetics: Efficient chiral selectors in enantioselective separations. *Polymer Bulletin*, **2002**, *48* (1), pp. 9-15.
154. Burguete, M.I., García-Verdugo, E., **Vicent, M.J.**, Luis, S.V., Pennemann, H., Graf Von Keyserling, N., Martens, J. New Supported β -Amino Alcohols as Efficient Catalysts for the Enantioselective Addition of Diethylzinc to Benzaldehyde under Flow Conditions. *Organic Letters*, **2002**, *4* (22), pp. 3947-3950.
155. Altava, B., Burguete, M.I., García-Verdugo, E., Luis, S.V., **Vicent, M.J.** FT-Raman as a simple tool for the fast monitoring of reactions on silica-supported reagents and catalysts: Application to silica-bound prolinol and TADDOLs *Tetrahedron Letters*, **2001**, *42* (48), pp. 8459-8462.
156. Altava, B., Burguete, M.I., García-Verdugo, E., Luis, S.V., **Vicent, M.J.**, Mayoral, J.A. Supported chiral catalysts: The role of the polymeric network. *Reactive & Functional Polymers*, **2001**, *48* (1-3), 25-35.
157. Altava, B., Burguete, M.I., García-Verdugo, E., Luis, S.V., **Vicent, M.J.** The use of NIR-FT-Raman spectroscopy for the characterization of polymer-supported reagents and catalysts *Tetrahedron*, **2001**, *57* (41), pp. 8675-8683.
158. Altava, B., Burguete, M.I., García, J.I., Luis, S.V., Mayoral, J.A., **Vicent, M.J.** A test for the coexistence of reactive intermediates with different molecular composition in chiral Lewis acid-catalysed reactions: The case of Ti-TADDOLate-catalysed Diels-Alder reactions *Tetrahedron Asymmetry*, **2001**, *12* (13), pp. 1829-1835.
159. Altava, B., Burguete, M.I., Collado, M., García-Verdugo, E., Luis, S.V., Salvador, R.V., **Vicent, M.J.** A general route for the preparation of polymer-supported N-tosyl aminoalcohols and their use as chiral auxiliaries. *Tetrahedron Letters*, **2001**, *42* (9), pp. 1673-1675.
160. Altava, B., Burguete, M.I., García-Verdugo, E., Luis, S.V., Miravet, J.F., **Vicent, M.J.** On the origin of changes in topicity observed in Diels-Alder reactions catalyzed by Ti-TADDOLates. *Tetrahedron Asymmetry*, **2000**, *11* (24), pp. 4885-4893.

161. Altava, B., Burguete, M.I., Fraile, J.M., García, J.I., Luis, S.V., Mayoral, J.A., **Vicent, M.J.** How important is the inert matrix of supported enantiomeric catalysts? Reversal of topicity with two polystyrene backbones. *Angewandte Chemie - International Edition*, **2000**, 39 (8), pp. 1503-1506.
162. Altava, B., Burguete, M.I., García-Verdugo, E., Luis, S.V., Salvador, R.V., **Vicent, M.J.** Polymerisation vs. grafting in the preparation of polymer-supported aluminium catalysts for the Diels-Alder reaction: The role of the polymeric backbone. *Tetrahedron*, **1999**, 55 (44), pp. 12897-12906.
163. Altava, B., Burguete, M.I., Fraile, J.M., García, J.I., Luis, S.V., Mayoral, J.A., Royo, A.J., **Vicent, M.J.** TADDOL-TiCl₂ catalyzed Diels-Alder reactions: Unexpected influence of the substituents in the 2-position of the dioxolane ring on the stereoselectivity *Tetrahedron Asymmetry*, **1997**, 8 (15), pp. 2561-2570.

Patents

1. M.J.Vicent, I. Conejos-Sánchez, C. Pegoraro, E. Karpova, G Sogorb, C Felip, VJ Nebot, P. Schwiller, Y. Qutbuddin Polyproline-based block copolymers. Application no.: EP23382668.4; Filing date: June 29, 2023; PCT/EP2024/068352 June 28, 2024 *PTS SL, CIPF, Max-Planck-Gesellschaft*. Publication date: January 02, 2025. Publication no.: WO 2025/003463
2. M. Martínez, J. Lorenzo, MJ Vicent, F. Novio, D. Montpeyo, E. Pradas, I. Conejos-Sánchez, D. Ruiz. Glucocerebrosidase (GBA) polymer conjugate, preparation method and use for nanotechnological based Enzyme Replacement Therapy. Application no.: EP22383152.0. Filing date: November 29, 2022. PCT/EP2023/083626 29/11/2023. WO2024115612A1. *VHIR, UAB, CIPF, CSIC, ICN2*.
3. R. Miravet Martí, L. Tortajada, L. Herrera, R. Roman, JJ Arroyo Crespo, C Felip, MJ Vicent, VJ Nebot. Star-shaped Graft Copolymers. Application no.: EP22382505.0 Filing date: May 26, 2022; PCT/EP2023/064072 25May2023; WO2023227724A1. *Polypeptide Therapeutic Solutions, S.L.*
4. D. Morelló Bolumar, R Miravet Martí, S Alonso De Castro, MJ Vicent, VJ Nebot. Polysarcosine-Vitamin E derivatives. Application no.: EP21383149.8. Filing date: 17Dec 2021. PCT/EP2022/086403 16Dec2022; WO2023111290A1 *Polypeptide Therapeutic Solutions, S.L.*
5. L. Herrera, I. Dolz, C. Felip, V. J. Nebot, M.J. Vicent. Star-shaped PAsp-oligoamine derivatives. Application no.: EP21382666.2. Filing date: July 22, 2021. PCT/EP2022/070604 July 22, 2022; WO2023002012A1. *Polypeptide Therapeutic Solutions, S.L.*
6. M.J. Vicent et al. Polymeric conjugates and uses thereof Application number: PCT/EP2020/058940. WO2020193802A1. Application date: 30/03/20. CIPF & Step by Step Foundation.
7. S. Schwartz, I. Abasolo, MJ. Vicent. Polyacetal based conjugates of taxol useful for the treatment of cancer. European Patent Application P5279EP00.EP19383184.9. Priority Date:23/12/19. *VHIR*
8. M. J. Vicent, et al. Cross polymers composed of polysaccharides and polyamino acids, and uses thereof European patent. EP17382498. WO2019020344A1. Priority date July 2017. *Polypeptide Therapeutic Solutions S.L. (PTS) in Exploitation*.
9. Cross-linked Star-shaped self-assembled polyglutamates and its use as carriers in biomedical applications. WO2017025298A1. European patent. Filed 07/08/2015. Published 16/2/2017 National Stages: Extension to EU, USA and Canada. USA and EU granted. *Licensed to PTS and in Exploitation*.
10. Polymeric conjugates for the treatment of amyloidosis. European patent EP13382184. WO2014187654A1 Priority date. 20/05/2013. CIPF and CSIC.
11. Novel controlled polyglutamates with versatile structure. 24/10/2011. P Int. Appl. No.: PCT/ES2012/070740. WO2013060919 A1. Extended to Europe and US (granted). *Licensed: Polypeptide Therapeutic Solutions S.L. (Spin Off co-founded by Dr Vicent) and in Exploitation*
12. Novel Nanoconjugates for treating bacterial infections. PCT/2010/30218. WO2010136617A1. Priority Date 28/05/2009. CIPF and CSIC.
13. Novel conjugates of polymers with a therapeutically active agent and an angiogenesis targeting moiety and uses thereof in the treatment of angiogenesis. WO/2009/141826. Priority Date: 22-05-2008. CIPF and Tel Aviv Univ.
14. Polymer conjugate compounds for the inhibition of apoptosis. WO/2008/141762. WO2008141762A2. Priority Date: 27/11/2008 and WO2008141762A3. Priority Date: 03/09/2009. CIPF and CSIC. *Licensed to Salvat Labs*.
15. Pharmaceutical composition for apoptosis inhibition. WO/2007/060524A1. Priority Date: 22/11/2006. CIPF and CSIC. *Licensed to Salvat Labs*.

Oral Communications - More than 300 communications in congresses, workshops, symposiums.

Selected Invited lectures, including Plenary talks and Keynotes (>150) are:

1. Polypeptide-Based Therapeutics: Unlocking Tropism and Crossing Biological Barriers. Future Materials 2025, Tenerife, Spain, 27-29 October 2025

2. Polypeptide-Based Nanomedicine: Unlocking Tropism and Biological Barrier Penetration for Advanced Cancer Therapy. ASEICA Bilbao, SPain, 8-10 October 2025
3. Polypeptide-Based Nanomedicine: Unlocking Tropism and Bypassing Biological Barriers. FBPS25, Porto, Portugal, 22-24 September 2025
4. Plenary Lecture: Polypeptide-Based Therapeutics from Bench to Clinic. Nanothera Summit, Valencia, Spain, 6-8 September 2025
5. Identification of Functional Biomarkers for Personalized Nanomedicine in Advanced Breast Cancer Models. Annual Meeting of the Controlled Release Society, Philadelphia, USA 14-18 July 2025
6. Polypeptide-Based Nanomedicine: Unlocking Tropism and Biological Barrier Penetration for Advanced Cancer Therapy. Gordon Research Conference Cancer Nanotechnology 2025, Luca, Italy 15-19 June 2025
7. Advancing Biomaterials: Biomimetic and Biohybrid Innovations. College of France, Paris, France 6 June 2025
8. Polypeptide-Based Nanomedicines: Enhancing Tropism and Overcoming Biological Barriers. Nanomedicine meets the Tumor Microenvironment 2025 (NanoTME 2025), Twente, Germany 5-7 May 2025
9. Encuentros Medina 2025. 21 Feb. 2025
10. Keynote Lecture. Polypeptide-Based Nanomedicine Unveiling Tropism and Biological Barrier Crossing Capabilities. Belstein Nanotechnology Symposium. Rudesheim, Germany. 4-6 September 2024
11. Keynote Lecture Polypeptide materials with inherent tropism targeting subcellular organelles. 50th IUPAC Macro 2024 World Polymer Congress 1-4 July 2024
12. *Keynote Lecture. Rationally Design Polypeptide-based Therapeutics. Seminar Series University North Caroline Chapel Hill. 19 June 2024*
13. *Plenary Lecture.* Polypeptide-based Nanomedicine Unveiling Tropism and Biological Barrier Crossing Capabilities POLY-CHAR 2024 conference Madrid, Spain. 28th -31st May 2024
14. *Plenary Lecture:* Polypeptide-based Nanomedicine Unveiling Tropism and Biological Barrier Crossing Capabilities Brighthlands Polymer Days 2024. Camelot Campus. Maastricht, NL. 27-28 May 2024
15. *Keynote Talk:* Polypeptide-based Nanomedicine Unveiling Tropism and Biological Barrier Crossing Capabilities ICRS Mumbai, India. 27-29 February 2024
16. *Plenary Talk.* Rational design and Therapeutic potential of polypeptide-based conjugates. XV Spanish-Portuguese Conference on Controlled Drug Delivery, Lisbon, Portugal. 14th – 16th February 2024
17. *Plenary Talk.* Multimodal Polypeptide-based Therapeutics bypassing Challenging Biological Barriers. ICONAN 2024. Barcelona, Spain. 14-17 January 2024.
18. Crosslinked Self-assembled Polypeptide-based Conjugates or Polymeric Micelles? 14th CLINAM Summit. 8 Oct. 2023 - 11 Oct. 2023. Basel, Switzerland.
19. Versatile Polypeptide-based Nanoconjugates for Multimodal Therapeutic Applications. Israel Local Chapter of the Controlled Release Society Annual Meeting. ICRS2023, 5-7 Sept 2023. Israel.
20. *Plenary Talk.* Versatile Polypeptide-based Nanoconjugates for Multimodal Therapeutic Applications. 13th International NanoMedicine Conference Pier One Sydney Harbour, Sydney, Australia. 19 – 21 June 2023
21. *Keynote Lecture:* Multimodal Polypeptide-based Nanoconjugates as Therapeutics. 12th International Colloids Conference. Mallorca, Spain 12-14 June 2023
22. Versatile Polypeptide-based Nanoconjugates for Multimodal Therapeutic Applications. Advanced Functional Polymers for Medicine 2023. Barcelona, Spain, 7-9 June 2023
23. *Plenary Talk.* Designing Personalized Polymer-based Combination Nanomedicines for Advanced Stage Breast Cancer Patients. SFNano2022, Strasburg, France 5-7 Dec 2022
24. *Keynote Lecture:* Polypeptide-based conjugates as versatile therapeutics. 2022 International Conference of the Korean Society of Pharmaceutical Sciences and Technology (KSPST). 1-2 Dec 2022
25. Polypeptide-based Nanoconjugates as Versatile Therapeutics. Seminar INMA-Impulse. Zaragoza 29th Sept 2022
26. Summer Course in Advanced Therapies. Polypeptide-based Therapeutics as Nanosized Medicines. UIMP. Santander 29th Aug-1st Sept 2022
27. Success stories - From Bench to Clinical Trials – Lessons Learned. CRS 2022 Annual Meeting and Exposition from July 11-15 in Montreal.
28. Polypeptide-based Nanoconjugates as Versatile Therapeutics. SFI Centre for Medical Devices (CÚRAM) Annual Summit 21-22 June 2022
29. Polypeptide-Based Multivalent Nanoconjugates as Modulators of Tumor Microenvironment. *Advanced Functional Polymers for Medicine (AFPM) 2022 conference.* Sophia Antipolis, Nice (France). June 1st to June 3rd 2022
30. *Keynote Lecture.* Polypeptide-based Nanoconjugates as Versatile Therapeutics NanoSpain 2022. Madrid (Spain) 17-18 May 2022
31. *Plenary Talk.* Versatile Polypeptide-based Therapeutics for Unmet Clinical Needs. GEP-SLAP 2022. San Sebastián, Spain 10-13 May 2022

32. *Keynote Lecture*. Polypeptide-Based Multivalent Nanoconjugates as Modulators of Tumor Microenvironment. Advanced materials and devices for nanomedicine (AMA4MED)- Virtual 2-3rd May 2022
33. Designing Personalized Polymer-based Combination Nanomedicines for Advanced Stage Breast Cancer Patients. CLINAM 2022. 1-3 May 2022. Virtual Meeting
34. *Keynote Lecture*. Polypeptide-based Conjugates for CNS disorders. 8th Galenos Conference. 27-28th April Valencia, Spain
35. Polypeptide-based Therapeutics as Versatile Nanomedicines. Seminars in Drug Discovery and Development ETH Zurich, Switzerland. 7th April 2022
36. *Keynote Lecture*. Polypeptide-based Nanoconjugates as Versatile Therapeutics. CRS Indian Local Chapter. Virtual Meeting. 24-25th February 2022
37. Round Table Participation. IV Jornada Anticipando la Medicina del Futuro. Instituto Roche Madrid, 30th Nov 2021. Publication: Informes Anticipando Nanomedicina. Nº de depósito legal: M-22297-2021. ISBN online: 978-84-09-34096-5
38. Keynote lecture. Polypeptide-based nanosystems with fine tune organ tropism. SDDN Conference Madrid 29-30 Nov 2021
39. Polypeptide-based therapeutics for CNS disorders. Virtual AFPM 2021. Advanced Functional Polymers for Medicine. 13-16 Jul 2021
40. Advances in Hydrogel Materials for Medical and Pharmaceutical Applications (Panel Member). iCANX Talks. Online Event. 07/05/21
41. Nanotherapies as single agents or in combination Therapy for the treatment of Prostate Cancer. V Edition 'Trobada d'investigadors i investigadores en càncer "ciutat d'Alcoi"' 22nd April 2021.
42. Polypeptide-Based Therapeutics for Regenerative medicine. Bioinspiration and Biomimetics in the Design of Novel Therapeutic Approaches Workshop. CRS Italian Chapter. 16th Dec 2020. keynote talk
43. Polypeptide-based therapeutics as versatile nanomedicines. ETPN2020 Virtual event October 2020 *Keynote Lecture*
44. Polypeptide-based conjugates as versatile therapeutics CLINAM2020 Virtual Event. October 2020
45. Polypeptide-based Nanoconjugates 1st Virtual Conference on Polymer Chemistry September 2020
46. Polypeptide-based Therapeutics as single agents and in combination therapy. SBAN Conference September 2020 *Keynote Lecture*
47. Polypeptide-based Nanotherapeutics for CNS disorders. Controlled Release Society Virtual Annual Meeting and Exposition, 29th June – 2nd July 2020.
48. Polypeptide-based Conjugates as Versatile Therapeutics, Institut de Ciència de Materials de Barcelona, Spain. 3 February 2020
49. Polypeptide-based Therapeutics. University of Barcelona, Spain. 26 February, 2020
50. Nanomedicina amb essència de dona. Setmana Ciència 2019, Universitat Jaume I, Villareal, Spain 14 November 2019
51. Polypeptide-based Conjugates as Versatile Therapeutics. ICONAN 2019 Munich, Germany, 16-18 October 2019
52. Polypeptide-based Conjugates as Versatile Therapeutics. APS Meeting Greenwich, London UK 11-13 September 2019
53. Polypeptide-based Conjugates as Versatile Therapeutics as single agents or in combination therapy, ACS Fall 2019 National Meeting in San Diego, CA, August 25 - 29, 2019
54. Polypeptide-based polyplexes to boost effective gene silencing in CNS disorders, ACS Fall 2019 National Meeting in San Diego, CA, August 25 - 29, 2019
55. Polypeptide-based Nanoconjugates as versatile Therapeutics. RSC Soft Matter 14th International conference on materials chemistry (MC14), Birmingham, UK, 9-11 July 2019
56. Rationally-Designed Polypeptide-Based Combination Therapeutics. GRC Cancer Nanotechnology, Vermont (USA). 23-28 June 2019
57. Polypeptide-based conjugates as versatile drug delivery carriers. Keystone Meeting Dublin, Ireland, 6-7 May 2019
58. Invited Lecture - Polypeptide-Based Conjugates as Versatile Anticancer Therapeutics. Bienal RSEQ San Sebastian, Spain. 28-30 May, 2019
59. Keynote Lecture - Polypeptide-based Conjugates for CNS disorders: Exploring the Intranasal Route of Administration, Frontiers in Biomedical Polymers - FBPS19, Tenerife, Spain, 19-23rd May 2019
60. Why are Proof of Concept Grants Relevant for Researchers? ERC Summit, Braga, Portugal, 8-9th April 2019
61. Polypeptides as versatile Drug Delivery Carriers. Biomaterials Discovery Workshop, University of Nottingham, UK. January 2019
62. Polypeptide-based conjugates as versatile therapeutics. Advanced theranostic nanomedicine in oncology, Pisa, Italy. January 2019

63. Targeting Tumor microenvironment with polypeptide-based nanoconjugates. Keynote Speaker. NanoBioMed Conference Barcelona, Spain. November 2018
64. Round Table on Advanced Materials. Fira Destaca, Vila-real, Spain, Nov 2018.
65. Polypeptide-based nanoconjugates as Therapeutics. Keynote Speaker. ASEICA, Valencia, Spain, Nov 2018.
66. Self-assembled Polypeptides as nanomedicines. IPTS2018. Antalya, Turkey Sept. 2018
67. Gordon Research Conference Carriers in Medicine. Boston, USA. August 2018
68. Control Architecture and Supramolecular Assembly In Polypeptide-based Conjugates2018 Annual Meeting Controlled Release Society. New York July 2018. Mini-Symposium co-chair and Invited speaker.
69. Conference on definitions on Biomaterials. Conference by Invitation only. Chengdu (China) June 2018.
70. Versatile Polypeptide-based Nanoconjugates as Therapeutics. Keynote Speaker. Summer School on "Fabrication of Multifunctional Biomedical Devices" Univ. Minho (Portugal) from the 3rd to the 6th of June 2018
71. Versatile Crosslinked Star-shaped Polypeptide Conjugates with Controlled Self-assembly as Therapeutics. AFPM 2018 conference. Montpellier (France) 16-18 May 2018.
72. Towards the Design of Personalised Polymer-based Combination Conjugates for Advanced Stage Breast Cancer Patients. Keynote Speaker. XII Spanish-Portuguese Conference on Controlled Drug Delivery, University of **Coimbra**, 2018
73. Polyglutamates as Versatile Drug Delivery Carriers. Plenary Speaker. Frontiers Polymer Science 2017 (FPS17), Spain. 2017.
74. Polyglutamates as nanosized medicine in neuroregeneration. Keynote Speaker. CESB2017, Porto (Portugal) 2017.
75. Polypeptides as Versatile Drug Delivery Nanocarriers Keynote Speaker. 11th Annual Symposium on Nanobiotechnology. Kawasaki (Japan) 2017.
76. Versatile Star-shaped Polypeptide Conjugates with Controlled Self-assembly as Therapeutics Italian Controlled Release Society 2017
77. Polymer Therapeutics 2nd SUMMER SCHOOL OF EUROPEAN & INTERNATIONAL SOCIETIES FOR NANOMEDICINE Barcelona 28/09/2017
78. Bridging early academic research & clinical development on polypeptide-based nanomedicines SLAS-Spanish Drug Discovery Network 20/09/2017
79. Polymer Therapeutics as Nanomedicines Postdam, Germany Helmholtz Institute 19/09/2017
80. Polymer Therapeutics and Stem cell therapies as a combinatorial approach for the treatment of chronic spinal cord injuries 254th American Chemical Society National Meeting and Exposition Washington DC, ACS 19/08/2017
81. PMSE18: Versatile star-shaped polypeptide conjugates with controlled self-assembly as therapeutics Washington DC, ACS 23/08/2017
82. Polymer-based Combination Therapeutics Global Conference on Pharmaceutics and DRug Delivery Systems Magnus Group 01/07/2017
83. Polyglutamates as Versatile Nanocarriers Reunion Bienal de la RSEQ Real Sociedad Española de Química 29/06/2017
84. Polyglutamates as versatile drug delivery carriers. Keynote Speaker. Gordon Research Conference on Drug Carriers in Medicine. Waterville (USA), 2016.
85. Polyglutamate based conjugates. Keynote Speaker. Macro UK Group. Warwick (UK), 2016.
86. Polymer conjugates as nano-sized medicines: from single agents to combination Therapies. Keynote Speaker. 10th World meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Glasgow (UK), 2016.
87. Polymer-drug conjugates as nanosized medicines. Instituto de Investigación de Enfermedades Raras, ISCIII. Madrid (Spain), 2016.
88. Imaging. B-Debate. Imaging for Life. From Molecules to Diagnostics and Therapy. Barcelona (Spain), 2016.
89. Polyglutamates as carriers in combination therapy. Keynote Speaker. Advanced Drug Delivery in Cancer: intracellular targets and vesicular carriers Conference. Manchester (UK), 2016.
90. Polymer anticancer conjugates as nanomedicines. Keynote Speaker. National World Cancer Day 2016 Barcelona (Spain), 2016.
91. Current Trends in Drug Delivery Systems. Keynote Speaker. Fresenius Kabi Workshop in Innovative Drug Delivery Systems. Bad Homburg (Germany), 2016.
92. Polymer Therapeutics as nanosized medicines. Univ. Castilla la Mancha. VI Workshop de Investigación en Farmacia. Albacete (Spain), 2016.
93. II SOGUG Symposium on Translational Research. Prostate cancer biOTypes towards a personalized Medicine: targeting the Igf1r pathway using polymer therapeutics (PROMIse). Barcelona (Spain), 2015.
94. Polyglutamate-based Polymer Therapeutics. Plenary Speaker. Spanish-Italian Medicinal Chemistry Congress (SIMMC-2015), Spain. 2015

95. Controlled polyglutamates for drug delivery applications. Keynote Speaker. German Peptide Symposium (GPS 2015). Darmstadt, Germany. 2015
96. M.J. Vicent. II SOGUG Symposium on Translational Research. Prostate cancer biOTypes towards a personalized Medicine: targeting the Igf1r pathway using polymer therapeutics (PROMIse). Barcelona (Spain), 2015.
97. M.J. Vicent. Polyglutamate-based Polymer Therapeutics. Plenary Speaker. Spanish-Italian Medicinal Chemistry Congress (SIMMC-2015), Spain. 2015
98. M.J. Vicent. Controlled polyglutamates for drug delivery applications. Keynote Speaker. German Peptide Symposium (GPS 2015). Darmstadt, Germany. 2015
99. M.J. Vicent. Polymer Conjugates as nanosized medicines in Combination Therapy. Keynote Speaker. Gordon Research Conference on Drug Carriers in Medicine and Biology. Boston, (USA), 2014.
100. M.J. Vicent. Polymer-drug conjugates as nanosized medicines. Keynote Speaker. Bionand Seminar Series. Málaga, Spain, 2014
101. M.J. Vicent Designing Polymer-based Combination Therapy for the Treatment of Cancer. Plenary Speaker. SCT-SFNano. When Medicinal Chemistry Meets Nanomedicine. Paris (France), 2014.
102. M.J. Vicent Polymer Conjugates as Nano-sized Medicines. Plenary Speaker. 4th International NanoMedicine Conference. Sydney Australia 2013.
103. M.J. Vicent Polymer Conjugates as Nano-sized Medicines. Plenary Speaker. Annual Symposium CIBER-BBN, Torremolinos, Spain 2013.
104. M.J. Vicent. Polymer Conjugates as Nano-sized Medicines. V Spanish Drug Discovery Network meeting. Valencia, Spain 2013.
105. M.J. Vicent. Exovesicles as vehicles for drug delivery. UIMP. Extracellular vesicles: implications in biomedicine. Valencia, Spain 2013.
106. M.J. Vicent. Polymer conjugates as single agents and in combination Therapy. Keynote Speaker. ESB. 25th European Conference on Biomaterials. Madrid, Spain 2013
107. V.J. Nebot, A. Duro-Castano, I. Conejos-Sanchez, R.M. England, M.J. Vicent Well-defined synthetic polypeptide based architectures as nanocarriers for drug delivery or imaging probes. Xth Spanish-Portuguese Conference on Controlled Drug Delivery. Drug Delivery Systems from Lab to Clinic. New trends and Opportunities. Valencia, Spain 2013
108. M.J. Vicent Polímeros Terapéuticos como Nanomedicinas. XXXVII Congreso Nacional de Immunología. Salamanca, Spain 2013.
109. A. Armiñán, M.J. Vicent. Polymer therapeutics as a nano-sized medicines. 1st GEIVEX Symposium. Extracellular vesicles "Implications and Opportunities in Biomedicine". Segovia, Spain 2012
110. M.J. Vicent Polymer conjugates as Combination Therapy. 1st Pan African Nanomedicine Summer School. Pretoria, South Africa. 2012
111. M.J. Vicent Polymer conjugates for Tissue Regeneration and Repair. 1st Pan African Nanomedicine Summer School. Pretoria, South Africa. 2012
112. M.J. Vicent. Polymer Conjugates as Nano-sized Medicines: from single agents to combination Therapy. Keynote Speaker. XXII International Symposium on Medicinal Chemistry (EFMC-ISMC) Berlin, Germany 2012
113. M.J. Vicent. Well-defined polyglutamates as drug delivery carriers. 76th Prague Meeting on Macromolecules Polymers in Medicine 2012-IUPAC. Prague, Czech Republic 2012
114. R. England, A. Duro, I. Conejos, A. Birke, M. Barz, M.J. Vicent. Well-defined Polyglutamates as versatile architectures for Drug Delivery. 9th Int. Symposium Polymer Therapeutics: From Lab to Clinic. Valencia, Spain 2012
115. M.J. Vicent. Polymer Conjugates as Nano-sized Medicines. 12th European Symposium on Controlled Drug Delivery Egmond aan Zee, The Netherlands 2012
116. M.J. Vicent. Polymer Conjugates as Nano-sized Medicines. I Reunión Biental del Grupo de Química Biológica. Santiago de Compostela, Spain 2012
117. M.J. Vicent. Polymer Conjugates as Nano-sized Medicines. Ponencia invitada. Mesa Redonda NANOMEDICINA: La última Frontera. Expoquimia 2011 Barcelona, España 2011
118. M.J. Vicent. Polymer-drug Conjugates as Single agents or in Combination Therapy. Nanomedicine and Drug Delivery Symposium NanoDDS'11 Salt Lake City, USA 2011
119. M.J. Vicent. Polymer-drug Conjugates as Single agents or in Combination Therapy: Future Trends, Challenges and Opportunities. III ESF Summer School in Nanomedicine Wittenberg, Germany 2011
120. M.J. Vicent. Polymer Conjugates as Single agents or in Combination Therapy: Versatile Platform Technology for Tissue Repair and Cancer Therapy. Ponencia invitada. EUROPEAN POLYMER CONGRESS 2011 (EPF2011) Granada, Spain 2011

121. M.J. Vicent Polymer conjugates use as single agents and combination therapy: A versatile 'technology platform' for tissue repair and cancer therapy. Escuela Nacional de Materiales Moleculares Benicassim, Castellón, Spain 2011
122. M.J. Vicent. Polymer conjugates use as single agents and combination therapy: A versatile 'technology platform' for tissue repair and cancer therapy. Workshop Spanish Nanomedicine Platform. CDTI, Madrid, Spain, 2011
123. M.J. Vicent. Polymer conjugates use as single agents and combination therapy: A versatile 'technology platform' for tissue repair and cancer therapy. ESF-UB Conference on Nanomedicine. San Feliu de Guixols, Spain, 2010
124. M.J. Vicent. Polymer therapeutics as versatile 'technology platform' for tissue repair and cancer therapy. Barcelona Innovation Workshops. Nanobiotechnology. INTERBIO. Barcelona, Spain. 2010
125. M.J. Vicent. Polymer conjugates use as single agents and combination therapy: A versatile 'technology platform' for tissue repair and cancer therapy. 240th American Chemical Society National Meeting and Exposition. Boston, USA. 2010
126. M.J. Vicent. Polymer conjugates as single agents or in combination therapy: Versatile platform technology for tissue repair and cancer therapy. IX SEQT Workshop, "NEW PERSPECTIVES AND EMERGING TECHNOLOGIES IN DRUG DISCOVERY" Baeza, Spain. 2010
127. Vanesa Giménez, C. Deladriere, I. Conejos, G. Ciofani, Y. Fernández, I. Abasolo, V. Felipe, S. Schwartz Jr., M.J. Vicent. Polymer-drug conjugates use as single agents and combination therapy: A novel 'technology platform' for tissue regeneration and cancer treatment. 6th International Key Symposium NANOMEDICINE, Stockholm, Sweden. 2009
128. M.J. Vicent Polymer Therapeutics: Nanopharmaceuticals from Lab to Clinic. Serie de conferencias del IBEC, Parc Científic Barcelona. Barcelona, Spain 2009
129. V. Giménez, C. Deladriere, I. Abasolo, Y. Fernández, S. Schwartz Jr, M.J. Vicent "Diseño de Nanoconjugados para el Tratamiento de Tumores Hormono-Dependientes." I Jornada de Nanomedicina de la Red Gallega de Nanomedicina, Vigo, Spain, 2008
130. M. J. Vicent. 'pH-responsive polyacetals as platforms for combination therapy'. 6th International Workshop on Drug Delivery Systems for Nanomedicine'. Prague, Czech Republic 2008
131. M. J. Vicent. 'pH-responsive DES-polyacetals for the treatment of hormone-dependent cancers'. British Pharmaceutical Congress. BPC2008. Manchester, UK. 2008
132. M. J. Vicent. "Polymer-drug Conjugates as Modulators of Cellular Apoptosis". 35th Annual Meeting & Exposition of the Controlled Release Society (CRS) New York, USA. 2008
133. M. J. Vicent, L. Mondragón, M. Orzáez, L. Dieudonné, A. Moure, A. Armijo, P. Sepúlveda, L. Peri, I. Goicoechea, A. Alcaraz, Á. Messeguer, E. Pérez-Payá. "Polymer Conjugates For The Treatment of Ischaemic Diseases" 7th International Symposium on Polymer Therapeutics: from Laboratory to Clinical Practice. Valencia, Spain, 2008
134. M. J. Vicent. "Novel Polymer Conjugates As Single Agents and For Delivery of Combination Therapy (Endocrine and Chemotherapy)." APV-Course on Drug Delivery for Oncology Therapies. Basel, CH, 2007
135. M. J. Vicent "Polymer Drug Conjugates as Anticancer Agents: Use as Single Agents and Combination Therapy." American Association Cancer Research (AACR) Annual Meeting 2007 Los Angeles, CA, USA. 2007
136. M. J. Vicent, L. Mondragón, M. Orzáez, A. Messeguer and E. Pérez-Payá "Novel polymer conjugate modulator of cellular apoptosis" 7th International Symposium on Polymer Therapeutics Berlin, Germany. 2007
137. M. J. Vicent, F. Greco, L. Mondragón, M. Orzáez, R.I. Nicholson, E. Pérez-Payá and R. Duncan "Polymer combination therapy: a novel approach to treat breast cancer " 4th Nanomedicine and Drug Delivery Symposium. NanoDDS'06 Omaha, Nebraska, USA 2006
138. M.J. Vicent, F. Greco, R. Nicholson and R. Duncan "Designing novel Polymer Conjugates for the Treatment of Hormone-dependent Cancers" 6th Symposium on Frontiers in Biomedical Polymers, FBPS05 Granada, Spain 2005

Organization of Scientific Meetings

1. **XVI SDDN Annual Conference.** Co-chairs: M.J. Vicent, M. Orzáez and E. Masià. CIPF, Valencia 13-15 Nov 2024
2. **VI ChemBIO Conference.** Specialized Chemical Biology Group of the RSEQ. Co-Chairs: MJ Vicent, B Escuder, R. Martínez-Mañez, I. Tuñón. 6-8 March 2023. CIPF, Valencia
3. **13th International Symposium on Polymer Therapeutics: From Lab. to Clinical Practice** International Conference. Organizers: M.J. Vicent. 23-25 May 2022. Valencia, Spain. (<http://ispt-conference.com>)
4. **SDDN Conference 2021.** 29-30th November Madrid
5. **SDDN Webinar series 2020.** Virtual conference 1st session 5th November 2020

6. **PMSE Symposium on Synthetic Polypeptides at ACS Annual Meeting.** International Conference Organizers: IMJ Vicent as co-Chair August 23-28 2019. San Diego, USA.
7. **46th Annual Meeting and Exhibition of the Controlled Release Society.** International Conference MJ Vicent as Chair July 21-23 2019. Valencia (Spain)
8. **Mini Symposia** titled Polymer Therapeutics Clinical Translation: Challenges and Opportunities taking place at the 2018 CRS Annual Meeting in New York City from July 22-24th. Polymer Therapeutics Clinical Translation: Challenges and Opportunities
9. **12th International Symposium on Polymer Therapeutics: From Lab. to Clinical Practice** International Conference. Organizers: M.J. Vicent. 28-30 May 2018. Valencia, Spain. (<http://ispt.cipf.es>)
10. **11th International Symposium on Polymer Therapeutics: From Lab. to Clinical Practice** International Conference. Organizers: M.J. Vicent. 23-25 May 2016. Valencia, Spain. (<http://ispt.cipf.es>)
11. **10th International Symposium on Polymer Therapeutics: From Lab. to Clinical Practice** International Conference. Organizers: M.J. Vicent and R. Duncan. 19-21 May 2014. Valencia, Spain.
12. **X Spanish-Portuguese Chapter of the Controlled Release Society** Conference Spain and Portugal. Organizer: MJ Vicent. 10-12 November 2013 Valencia, Spain
13. **V Annual meeting of the Spanish Drug Discovery Network.** National Conference. Organizers: M.J. Vicent and M.C. Alvarez. Date: 24-25 October 2013, Valencia (Spain)
14. **Frontiers in Polymer Science.** International Symposium. Organizers: Stephen Z.D. Cheng, and Axel H. E. Müller, Role: Local co-chair (JM Kenny and MJ Vicent). 21 – 23 May 2013. Sitges, Spain
15. **9th International Symposium on Polymer Therapeutics: From Lab. to Clinical Practice** International Conference. Organizers: M.J. Vicent and R. Duncan. 28-30 May 2012. Valencia, Spain.
16. **XVI Congreso de la Sociedad Española de Química Terapéutica.** National Conference Organizers: A. Pineda-Lucena. Role: Member Organising Committee. 18- 21 September 2011. Valencia, Spain.
17. **3rd ESF-Summer School Nanomedicine.** International Summer School. Chair: K. Mäder. Co-Chairs: H Foth, R Gaspar, C Kloft, MJ Vicent. 19 – 24 June 2011. Halle-Wittenberg, Germany
18. **Macro 2010 IUPAC World Polymer Congress. Symp. Polymers in Therapeutics. Polymer Nanomedicines.** Int. Symposium. Organizers: Battaglia, Kenny, Vicent. 11–16 July 2010. Glasgow, UK.
19. **Workshop SPLC-CRS. Drug delivery Technologies: From Lab to Clinic.** Workshop Spain-Portugal. Chair: M.J. Vicent Co-organizers: A Fernández, C Montejo. 28 May 2010. Valencia, Spain
20. **8th International Symposium on Polymer Therapeutics: From Lab. to Clinical Practice** M.J. Vicent, R. Duncan co-chairs. 24-26 May 2010. Valencia, Spain
21. **7th International Symposium on Polymer Therapeutics: From Laboratory to Clinical Practice** M.J. Vicent and R. Duncan co-chairs. 26-28 May 2008. Valencia, Spain
22. **VIII Spanish-Portuguese Chapter of the Controlled Release Society** Conference Spain-Portugal. Organizers: A.I. Torres. M. Guzmán. Role: Scientific committee 20-22 October 2008, Madrid, Spain.

Scientific Supervision (not considering undergraduates)

Currently ongoing at the Polymer Therapeutics Lab at CIPF: 3 Senior researchers/4 Postdoctoral fellows / 13 PhD students (4 as Industrial PhD) / 3 technicians/1 Project manager/2 MSc Students/

Past supervision to: 22 PhD students (*moving to:* Lecturer at Reading (UK), Postdocs in academia (Centre Méditerranéen de Médecine Moléculaire (France); Univ. Santiago Compostela (Spain), British Columbia in Canada) UCL (UK), Position in industry (Novartis (USA), PTS/Curaph (Spain), Tosoh (Germany) or in research centers (CIDETEC (Spain)). 12 Postdoctoral Fellows (*moving to:* Merck-Serono, AstraZeneca, Junior PI at Monash Univ. (Australia), Habilitant at Mainz Univ. (Germany), Professor at Leiden Univ (NL), Professor at Padova Univ (IT, ERC Starting grant), senior postdocs at CNB or FIVO (Spain), UCL (UK), Louvain (Belgium)...Lecturer in France, CTO, CSO or project manager at Curaph....) 3 technicians and 13 visiting PhD students

Defended PhD thesis supervised

1. **Title: Identification of new biomarkers and the development of combination polymer conjugates in metastatic prostate cancer**

Student: Antoni Serrano Martí (Co-supervised A Armiñán) (ACIF grant)

University: Centro de Investigación Príncipe Felipe Date: 13th June 2025

Mark: Excellent Cum Laude with an option for the Extraordinary Ph.D. prize. International PhD

2. **Title: Mitochondria-targeted ROS mediated polypeptide-drug conjugate delivery platforms**

Student: Camilla Pegoraro (Co-supervised I Conejos-Sánchez) (ITN-Biomolmacs)

University: Centro de Investigación Príncipe Felipe Date: 16 April 2025

Mark: Excellent Cum Laude with an option for the Extraordinary Ph.D. prize. International PhD

3. Title: Development of a polymeric combination therapy for the treatment of metastatic triple negative breast tumors

PhD Student: Paz Boix Montesinos (co-supervised A Armiñán) (FPU grant)

University: Centro de Investigación Príncipe Felipe Date: 12th September 2024

Mark: Excellent Cum Laude with an option for the Extraordinary Ph.D. prize. International PhD

4. Title: New Developments on metabolomics by NMR

Student: Ines Domingo Ortí (FPU grant)

Co-director of thesis: Martina Palomino; Antonio Pineda Lucena

Entity: IISLaFe and CIPF Date: 19 April 2024

Mark: Excellent Cum Laude with an option for the Extraordinary Ph.D. prize. International PhD

5. Title: Brain drug delivery using polymer therapeutics as intranasal platform towards paediatric glioma treatment

PhD Student: Tetiana Melnyk (AECC Grant) (Co-supervised with Dr Conejos-Sanchez)

Entity: Centro de Investigación Príncipe Felipe Date: 7th March 2024.

Mark: Excellent Cum Laude with an option for the Extraordinary Ph.D. prize. International PhD

6. Title: Development of Analytical Procedures for The Characterization Of Polypeptide-Based Nanoconjugates

PhD Student: Snežana Đorđević

University: Centro de Investigación Príncipe Felipe. Date: 24th May 2023

Mark: Excellent Cum Laude with an option for the Extraordinary Ph.D. prize. International PhD

7. Title: Inflammatory Tumor Microenvironment as Target in the Design of Nanoconjugates for the Treatment of Advanced Breast Cancer (InflaNanoTarget)

PhD Student: Paula Soriano Teruel (co-Supervised with Mar Orzáez)

Entity: Centro de Investigación Príncipe Felipe Dpt: Advanced Therapies

Date: 27th January 2023 Mark: Excellent Cum Laude with an option for the Extraordinary Ph.D. prize

8. Title: Design of novel targeted Polymer Therapeutics as combination therapy for the treatment of Brain Metastasis – Overcoming the Blood Brain Barrier

PhD Student: Fernanda Rodríguez Otormín (AECC Grant) (Co-supervised with Dr Duro-Castaño)

University: Centro de Investigación Príncipe Felipe Dpt: Advanced Therapies

Date: 7th April 2022

Mark: Excellent Cum Laude with an option for the Extraordinary Ph.D. prize. International PhD

9. Title: Polypeptidic carriers for the topical delivery of actives and therapeutics

PhD Student: Daniel Morelló Bolumar (Industrial PhD)

Entity: Polypeptide Therapeutic Solutions SL / CIPF

Date: 21/06/2021 Mark: Excellent Cum Laude with an option for the Extraordinary Ph.D. prize

10. Title: Development of Polymer-based Therapeutics for the Treatment of Castration Resistant Prostate Cancer

Student: Sonia Vicente-Ruiz (Co-supervised with Dr. Ana Armiñán)(FPI grant)

University: Centro de Investigación Príncipe Felipe Dpt: Advanced Therapies Date: 15/07/2020

Mark: Excellent Cum Laude with an option for the Extraordinary Ph.D. prize. International PhD

11. Title: Design of Polypeptide-based self-assembled therapeutics for Personalised Medicine in Breast cancer

Student: Oleksandr Zagorodko (Co-supervised with Dr. Vicent Nebot) Date: 11/05/2020

Mark: Excellent Cum Laude with an option for the Extraordinary Ph.D. prize

12. Title: Design of polypeptide-based drug delivery systems for topical administration

PhD Student: Irene Dolz Pérez (ACIF grant; Co-supervised with Dr Nebot)

University: Centro de Investigación Príncipe Felipe

Date: 26/11/19 Mark: Excellent cum Laude. International PhD

13. Title: Design of Polymer-based combination conjugates for breast cancer

PhD student: Juan Jose Arroyo Crespo (co-supervised with Dr Armiñán)

University: Centro de Investigación Príncipe Felipe

Date 12/11/18 Mark: Excellent cum Laude. International PhD

Extraordinary PhD award in Biomedicine by University Valencia

14. Title: 'Well-defined polyglutamates as non-viral vectors for cytosolic delivery'.

PhD Student: Amaya Niño Pariente (FPI grant) University: CIPF -UV

Date: 24th July 2017 Mark: Excellent cum Laude. International PhD

15. Title: Nanomedicine and Polymeric supports for Stem Cell Differentiation

PhD Student: Gabriela de Jesús Rodríguez Escalona (Co-supervised Prof. M. Monleón)

University: Centro de Investigación Príncipe Felipe and Univ. Politécnica de Valencia (UPV)

Date: 16 Feb 2016 Mark: Excellent Cum Laude

16. Title: Defining new biotypes in Prostate Cancer for diagnosis, prognosis and therapeutic intervention

PhD Student: Irene Casanova-Salas (FIS grant) (Co-supervised with Dr JA López-Guerrero and J. Rubio)

University: FIVO and Centro de Investigación Príncipe Felipe

Date: 30 June 2015 Mark: Excellent cum Laude. International PhD

17. Title: Polyglutamates as carriers for the treatment of neurodegenerative disorders

PhD Student: Aroa Duro Castaño (FPU grant)

University: Centro de Investigación Príncipe Felipe

Date: 8 October 2015 Mark: Excellent cum Laude. International PhD

Extraordinary PhD award in Biomedicine by University Valencia

18. Title: Polymer-based Combination conjugates for the treatment of Breast Cancer

PhD Student: Coralie Deladriere (FPI grant).

Date: 17 September 2013 Mark: Excellent cum Laude

19. Title: Rational design of polymer conjugates for the treatment of neurological disorders

PhD Student: Inmaculada Conejos Sánchez (FPU grant).

Date: 30 July 2013

Mark: Excellent cum Laude. International PhD

International PhD 2º award to the best PhD thesis of the SPLC-CRS

20. Title: pH-responsive Polyacetals for the treatment of Hormone-dependent cancer

PhD student: Vanessa Giménez Navarro.

Date: 30 November 2012.

Mark: Excellent cum Laude *Extraordinary PhD award in Biomedicine by University Valencia*

21. Title: Caracterización del mecanismo de acción del peptido 1 y sus derivados como inhibidores de la formación del apoptosoma. Búsqueda de nuevos moduladores del apoptosoma

PhD student: Laura Mondragón Martínez (co-supervised with Dr E. Pérez-Payá)

Date: 8 July 2009. Mark: Excellent cum Laude. International PhD

22. Title: Synthesis and evaluation of a new class of polymer conjugates for the treatment of Hormone-dependent cancers

PhD student: Francesca Greco (co-supervised with Prof R. Duncan y Prof R.I. Nicholson)

University: Cardiff University, Cardiff, UK Welsh School of Pharmacy. 8th May 2006 Mark: Pass

Ongoing PhD Thesis

23. Title: Polypeptide-based carriers as delivery platforms

Student: Ekaterina Karpova (Co-supervised A Duro-Castaño) (ITN-Biomolmacs)

University: Centro de Investigación Príncipe Felipe and PTS SL. Date: To be defended in April 2025

24. Title: Synergistic Approach for Neurodegenerative Disorder Treatments using Versatile PolyPeptide-based Conjugates

PhD Student: María Ibañez (co-supervised M Medel) (FPI grant)

University: Centro de Investigación Príncipe Felipe Date to be Defended: 2026

25. Title: Design of Polymer Conjugates for Glioblastoma treatment

PhD Student: Amina Benaicha (co-supervised I Conejos-Sánchez) (AECC-CV PhD grant)

University: Centro de Investigación Príncipe Felipe Date to be Defended: 2026

26. Title: Development of polypeptide based materials

Student: Luz Tortajada Comeche (Co-supervised C Felip) (EMPLEA, Industrial PhD with PTS S.L.)

Date: To be defended in 2027

27. Title: Development of analytical methods to fully Characterized polypeptide-based materials

Student: Silvia Stifano (Co-supervised S Abad and JJ Arroyo-Crespo (Industrial PhD with PTS S.L.)

Date: To be defended in 2027

28. Title: Designing Supramolecular Polypeptide-Based Therapeutics for Spinal Cord Injury

PhD Student: Karolina Gwizala (MSCA ITN MULTISMART network co-supervised with V. Moreno)

University: Centro de Investigación Príncipe Felipe

Date to be Defended: 2027

29. Title: Low Mw peptidic gelators for Biomedical applications

PhD Student: Martina LaMana (MSCA ITN MULTISMART network, co-supervised with Beatriu Escuder)

University: Universitat Jaume I (UJI) Date to be Defended: 2027

30. Title: Spatial Transcriptomics and Cell Communication Models applied to tissue regeneration and treatment in Spinal Cord Injury with Precision Nanomedicine.

PhD Student: Margarita Gubina (Prometeo Cells2Spain network)

University: Centro de Investigación Príncipe Felipe Date to be Defended: 2027

31. Title: A Multimodal Precision Polypeptide-based Nanoplatfom to Treat and Monitor Metastatic Castration Resistance PCa

PhD Student: Nerea Manzano (FPI, PID2023)

University: Centro de Investigación Príncipe Felipe Date to be Defended: 2028

32. Title: NanoInBrain Platform Applied for the treatment of Brain Metastasis from Breast Cancer

PhD Student: Leire Miguela (ACIF grant)

University: Centro de Investigación Príncipe Felipe Date to be Defended: 2028

33. Title: Precision ImmuneNanoTherapy targeting tumor-immune-stroma interactions against pancreatic cancer.

PhD Student: Carla Ortuño (La Caixa Health Research-PINT)

University: Centro de Investigación Príncipe Felipe Date to be Defended: 2028

34. Title: Novel nanocarriers as non-viral vectors for the treatment of Glioblastoma.

PhD Student: Valentina Zazza (ITN- NATPRIME)

University: Centro de Investigación Príncipe Felipe Date to be Defended: 2029

35. Title: Non-viral vectors with mitochondria tropism

PhD Student: Tanibet Alba O'Reily (ITN- NATPRIME)

University: Centro de Investigación Príncipe Felipe Date to be Defended: 2029

36. Title: Development and Preclinical Validation of a Multivalent Nanovaccine for the Treatment of Peritoneal Carcinomatosis

PhD Student: Maria Caballer Sanchis (FPU grant)

University: Centro de Investigación Príncipe Felipe Date to be Defended: 2029

37. Title: Innovative dual nano-immunotherapy for pancreatic ductal adenocarcinoma (PDAC)

PhD Student: Tiago André Silva Fidalgo (FCT grant, co-supervised with prof Florindo and Prof Graça

University: University of Lisboa Date to be Defended: 2029

Teaching Activities

2025-now Medicine Department Univ Jaume I, Castellón, Spain. Master on Translational Oncology

2025 Professor at the Advanced Materials School ESAM 2025, Almagro, Ciudad Real

2022 External professor at Winter school 'Injectable and Implantable polymeric drug delivery systems'. International Cooperation Amirkabir University of Technology.

2020-now Coordinator Erasmus+ Program CIPF- Mainz University (Germany)

2019-now Coordinator Erasmus+ Program CIPF- HOGENT University of Applied Sciences and Arts (Belgium)

2018-now Master course on Advanced Therapies. PhD program Biomedicine. CIPF, Valencia, Spain

2016-now Student exchange program Coordinator (EACH Consortium) ERASMUS+ program. CIPF-Univ Tartu (Estonia)

2012-2015 Associate Professor. Organic Chemistry Dpt. Univ. Valencia, Spain

2010-now Master course on Applied Chemistry and Pharmacology. Univ. Jaume I, Castellón Spain

2010-now Coordinator Erasmus+ Program on Pharmaceutical Sciences and Nanomedicine CIPF-Univ Ghent (Belgium).

2006 National and international courses on Nanomedicine and Drug Delivery, in Spain, South Africa, Germany, Switzerland and Portugal.

2004-now External Practicum Tutor from University of Valencia, Univ Politechnic Valencia, Catholic Univ Valencia, and Univ Jaume I (Castellón)